Thema: Peregrine Pharmaceuticals - BIOS u. PHARMAS international - 17 - 500 Beiträge pro Seite (Seite 2)

[funworker1]

na, ist das nicht schön ? wir bleiben unserem rhythmus treu.
das ist wirklich ein traum ! ;-) ;-) aber die news sind noch OK.

[funworker1]

war ja heute, am letzten handelstag für pphm im russell,
nochmal richtig volumen am start.
schauen wir mal, wie es jetzt weitergeht.

[asics01]

Druck- email

Medizinische Universität von Südcarolina leitet neuen Versuch von Cotara (R) bei Gehirn-Krebs-Patienten ein
6/26/2007


TUSTIN, Calif., 26. Juni /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc., eine klinisches Stadium biopharmaceutical Firma, die gerichtete Antikörper für die Behandlung des Krebses und der Virusinfektion der Hepatitis C, heute verkündet entwickelt, daß die medizinische Universität von Südcarolina (MUSC) jetzt Patienten in einem Dosisbestätigung und -dosimetrieversuch seiner Tumornekrosetherapie (TNT) Cotara (R) bei Patienten mit glioblastoma multiforme (GBM) einschreibt, eine tödliche Form des Gehirnkrebses. Cotara wird auch an anderen klinischen Aufstellungsorten in den US und in einem Multicenter Phase II Versuch in Indien studiert.

MUSC leitete Probeleitung Dr. Sunil Patel frühere Studien von Cotara bei GBM Patienten, die vielversprechende Zeichen der Antitumortätigkeit zeigten, einschließlich einen Patienten, der noch die lebendigen sechs Jahre Nachbehandlungs ist, wenn die meisten Patienten mit rückläufigem GBM nur ein ungefähr Jahr leben.

„Gründete auf den positiven Resultaten uns Säge in den vorherigen klinischen Studien von Cotara bei Patienten mit rückläufigem Gehirnkrebs, freue mich ich, diese neue Studie zu führen,“, sagte Sunil Patel, M.D., klinischer Vorsitzender der MUSC Abteilung von Neurologie. „Glioblastoma bleibt eine tödliche Krankheit mit wenigen guten Behandlungwahlen, und ich freue, Cotaras klinisches Potential mit Konvektion-erhöhter Anlieferung festzusetzen, die das verlängernde Potential des Lebens weiter verbessern kann, das gesehen wird in frühere Cotara Versuche.“

Diese geöffnete Aufkleberstudie schreibt glioblastoma Patienten ein, die rückläufige Krankheit haben. Patienten empfangen Cotara durch Konvektion-erhöhte Anlieferung (CED), eine NIH-entwickelte Technik, die das Mittel an den Tumor mit großer Präzision liefert. Die Hauptzielsetzungen der Studie sind, die maximale zugelassene Dosis zu bestätigen; Strahlung Dosimetrie feststellen; und gesamtes geduldiges überleben, Weiterentwicklung freies überleben und den Anteil den Patienten lebendig bei sechs Monaten Cotara folgend einschätzen Leitung.

„Unsere Bemühungen beschleunigen diese kritischen Cotara Studien in den US und Indien tragen jetzt Frucht, mit Einschreibung unterwegs in der die 40 Patient Phase II Studie in Indien und im USdosisbestätigung und -dosimetrieversuch, der gut,“ fortfährt, sagte Steven W. König, Präsidenten und CEO von ausländischem. „Wir glauben, daß diese Bemühungen erheblich durch die Hinzufügung des neuen Versuches an MUSC verstärkt werden, das Cotara vom sachverständigen Dr. Patel geführt wird. Cotara könnte eine wichtige neue Wahl für die Behandlung dieser tödlichen Krankheit möglicherweise zur Verfügung stellen, die wirkungsvolle Therapien ermangelt. Wir freuen, zu arbeiten, mit allen unsere Forscher, zum der klinischen Daten dieses Jahr zu erzeugen, das für die Bestätigung des Potentials von Cotara für die Behandlung des Gehirnkrebses kritisch sein sollte.“

Ausländisch arbeitet direkt mit mehreren seiner neuen Annäherungen zu den klinischen Aufstellungsorten der Gehirn-Tumor-Therapie (NABTT) in den US und mit zusätzlichen Mitten wie MUSC, um die fristgerechte Beendigung des USdosisbestätigung und -dosimetrieversuches sicherzustellen. Das Design dieser neuen Cotara Studie ist eine geänderte Version des Protokolls, das für das NABTT Programm entwickelt wird.

Über Cotara (R)

Cotara ist eine experimentelle neue Behandlung für Gehirnkrebs, der eine radioaktive Substanz verbindet, die für medizinischen Gebrauch bestimmt ist -- ein radioaktives Isotop -- zu einem gerichteten monoclonal Antikörper. Dieser monoclonal Antikörper ist entworfen, um an eine Art DNA zu binden, die nur auf den toten und sterbenden Zellen herausgestellt wird. Feste Tumoren, einschließlich Gehirntumoren, haben eine bedeutende Anzahl von toten und sterbenden Zellen in ihrer Mitte, und Cotaras zielende Einheit ermöglicht ihr, innen auf diesen sterbenden Tumorzellen abzuziehen und liefert seine radioaktive „Nutzlast“ direkt an die Mitte der Tumormasse. Cotara zerstört folglich den Tumor „vom Innere heraus,“ mit minimaler Strahlenbelastung zum gesunden Gewebe.

Cotara wird durch eine spezielle Methode geliefert, die Konvektion-erhöhte Anlieferung (CED) genannt wird, die Cotara auf den Tumor verweist, indem es einen Katheter verwendet, um die Blutgehirnsperre zu überbrücken und den spezifischen Tumoraufstellungsort im Gehirn zu zielen. Diese Art der Anlieferung ist gezeigt worden, um bis zu einer 10.000 Falte grösseren Konzentration in der lokalen Therapiebelichtung als herkömmliche intravenöse Drogeleitung zu erzielen, bei der Minderung der unerwünschten Aussetzung zum gesunden Gewebe.

In den vorhergehenden klinischen Studien hat Cotara anregenresultate bei Patienten mit vorgerücktem Gehirnkrebs gezeigt. Eine Studie zeigte eine 58% Zunahme der mittleren überlebensdauer in einer Gruppe Patienten, die unter spätem Stadium glioblastoma multiforme leiden, die mit Cotara behandelt wurden. Dieses galt als eine vielversprechende Entwicklung in dieser ernsten und tödlichen Krankheit. Zusätzlich zum Versuch jetzt unterwegs in Indien, ist Cotara z.Z. in einem Dosimetrie- und Dosisbestätigung Versuch bei glioblastoma Patienten an einer Zahl des Führens USder akademischen Gehirn-Krebsmitten. Cotara ist orphan Drogestatus und schnelle Schiene Kennzeichnung für die Behandlung von glioblastoma multiforme und von anaplastic astrocytoma durch die USnahrungsmittel-und Droge-Leitung bewilligt worden.

Über MUSC

Gegründet 1824 in Charleston, ist die medizinische Universität von Südcarolina die älteste medizinische Schule im Süden. Heute setzt MUSC die Tradition der hervorragender Leistung in der Ausbildung, in der Forschung und in der geduldigen Obacht fort. MUSC ist über zu 3.000 Kursteilnehmern und zu Bewohnern, sowie fast 10.000 Angestellte, einschließlich 1.300 Lehrkörpermitglieder Haupt. MUSC läßt eine medizinische Mitte mit 600 Betten laufen, die ein Krankenhaus und ein führendes Institut der national anerkannten Kinder der Psychiatrie einschließt. http://www.musc.edu

Über ausländische pharmazeutische Produkte

Peregrine Pharmaceuticals, Inc. ist eine biopharmaceutical Firma mit einer Mappe der erfinderischen Produktanwärter in den klinischen Versuchen für die Behandlung des Krebses und der Infektion des Virus der Hepatitis C (HCV). Die Firma übt drei verschiedene klinische Programme im Krebs und HCV Infektion in den US und im Indien mit seinem Leitung Produkt-Anwärterbavituximab und Cotara aus (R). Ausländisch hat auch innerbetriebliche Herstellung Fähigkeiten durch sein insgesamt besessenes Tochteravid Bioservices, Inc. (http://www.avidbio.com),, das Entwicklung und Bio-herstellung Dienstleistungen für die ausländischen und äußeren Kunden zur Verfügung stellt. Zusätzliche Informationen über ausländisches können bei http://www.peregrineinc.com gefunden werden.

Sichere Hafen-Aussage: Aussagen in diesem Pressekommuniquã#, die nicht, einschließlich die Aussagen betreffend sind Absichten der ausländischen pharmazeutischen Produkte, Hoffnungen, Glaube, Erwartungen, Darstellungen, Projektionen, Pläne oder Vorhersagen der Zukunft lediglich historisch sind, Vorwärts-schauen Aussagen innerhalb der Bedeutung der privaten Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995. Die Vorwärts-schauenden Aussagen beziehen Gefahren und Ungewißheiten einschließlich mit ein, aber begrenzt nicht auf, die Gefahr, die Resultate der zukünftigen Studien möglicherweise nicht, um Resultate prior zu studieren, oder die aufeinander beziehen können Cotara wirkungsvoller in verlängernder überlebensdauer als gegenwärtige Therapien ist. Es ist wichtig, zu merken, daß die tatsächlichen Resultate der Firma von denen in irgend solchen Vorwärts-schauenden Aussagen materiell sich unterscheiden konnten. Faktoren, die tatsächliche Resultate veranlassen konnten, sich materiell zu unterscheiden, schließen ein, aber werden nicht auf, die Ungewißheiten begrenzt, die mit dem Durchführen der preclinical und klinischen Versuche für unsere Technologien verbunden sind; das frühe Stadium der Produktentwicklung; die bedeutenden Kosten, zum unserer Produkte als alle unsere Produkte zu entwickeln sind z.Z. in der Entwicklung, in den preclinical Studien oder in den klinischen Versuchen; Erhalten der zusätzlichen Finanzierung, um unsere Betriebe und die Entwicklung unserer Produkte zu stützen; Erreichen der Genehmigung durch die zuständige Aufsichtsbehörde für unsere Technologien; vorweggenommenes TIMING der regelnden Archivierungen und der mögliche Erfolg beim der Gewinnung von Genehmigung durch die zuständige Aufsichtsbehörde und Einwilligen mit den Regierungsregelungen anwendbar auf unser Geschäft. Unser Geschäft könnte durch eine Anzahl von anderen Faktoren, einschließlich die Gefahr Faktoren beeinflußt werden, die gelegentlich in den Reports sek der Firma einschließlich verzeichnet wurden, aber begrenzt nicht auf, beendeten der jährliche Bericht über Form 10-K für das Jahr beendet 30. April 2006 und der vierteljährliche Bericht über Form 10-Q für das Viertel 31. Januar 2007. Die Firma warnt Investoren, übermäßiges Vertrauen nicht auf die Vorwärts-schauenden Aussagen zu setzen, die in diesem Pressekommuniquã# enthalten werden. Peregrine Pharmaceuticals, Inc. dementiert jede mögliche Verpflichtung und beabsichtigt, keine Vorwärts-schauenden Aussagen in diesem Pressekommuniquã# zu aktualisieren oder zu verbessern.

Kontakte: GendeLLindheim BioCom Partner-Investor-Mittel [e-mail] Barbara Lindheim [phone] [phone]

Peregrine Pharmaceuticals, Inc.
KONTAKT: Investoren, 800-987-8256, [e-mail] oder Mittel, BarbaraLindheim, [phone], beide von GendeLLindheim BioCom Partnern, forPeregrine Pharmaceuticals, Inc.

Web site: http://www.peregrineinc.com/http://www.musc.edu/

[funworker1]

und gädda,

schon die news gehört ? 30 000 000 neue shares zu 0,75 cent.
eine weitere verwässerung. so langsam geht mir das voll ..

[funworker1]

anscheinend ist keiner von w:o in pphm investiert. OK

gädda,

die 30 000 000 neue shares müßten doch eigentlich aus der ankündigung vom 12.01.07 stammen , oder ?

gruß
funworker1

[funworker1]

hier mal eine antwort auf eine mail von mir zu den
neu ausgegebenen shares. die antwort kam schon recht schnell.


PPHM - IR <[e-mail]>
02.07.2007 21:28
Peregrine's financing was essential if the company is to advance its three clinical programs, progress to the stage where partnering is both attractive and feasible and build sustainable value into the stock. We regret your frustration at this necessary action. We obtained adequate capital for the next year, secured investment banking support and laid the groundwork for analyst coverage as part of this financing, all positive developments. In addition, the 16% discount is right in line for other biopharma deals currently being done under a PIPE model and we did not have to issue any warrants , all, in our view positive developments.

We appreciate your support of Peregrine.

[gädda]

Antwort auf Beitrag Nr.: 30.463.932 von funworker1 am 03.07.07 09:33:06

Hallo funworker,

hat mich auch voll erwischt und bin leider auch stark betroffen.

So gut es sich alles im Medtechbereich von PPHM anhört, so schlecht ist es eben um die ewigen Finanzspritzen bestellt.

Ja was tun ?

gädda

[funworker1]

hallo gädda,

was tun ? ja, gute frage.

hast du die antwort von pphm auf meine mail gelesen ? klar
sagt jetzt nicht die welt aus. aber im grunde haben sie ja recht.
wer von den großen (hast du ja auch schon gesagt) haut jetzt schon
kohle für partnerschaften raus. keiner oder kaum jemand.
demnach ist die einzige chance weiter zu leben eine klassische
spritze. wenn die weiteren tests wirklich erfolg haben sit diese
verwässerung nicht der rede wert und wir werden ein vielfaches erhalten. aber da ich nicht in die zukunft schauen kann, hätte ich mir den letzten sparen können. aber seis drumm.

habe heute noch einmal 2000 stck nachgelegt. für den moment war es sicher klug. aber ich habe pphm nur als absoluten langfrist im auge.

weißt du, ob die 30 000 000 shares die angemeldeten aus den januar sind ? habe ich dich oben schon einmal gefragt.

bis dann

funworker1

[gädda]

Antwort auf Beitrag Nr.: 30.477.373 von funworker1 am 03.07.07 21:58:36

Hallo funworker,

du sagst es - Deine Ausführung kann ich nur bestätigen.
Aber wir wissen nicht ob es stimmt !
Haben die wirklich einen dicken Fisch ?

Zu den shares kann ich keine klare Antwort geben.
Es scheint so das die im Januar angemeldet wurden. Aber King hatte gesagt, daß es nicht zu einer neuen Verdünnung kommen würde, sondern eine andere Finanzierung getätigt würde ??? ist nicht so gekommen.

Jetzt wäre wichtig, daß die Bilanz einigermaßen okay ist insbesondere was die Erträge von AVID angeht.

Gruss und viel Glück

gädda

[AMDlong]

Press Release Source: Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2007
Wednesday July 11, 7:00 am ET

TUSTIN, Calif., July 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the fiscal year ended April 30, 2007. The company reported a consolidated net loss of $20,796,000, or $0.11 per basic and diluted share, compared to a consolidated net loss of $17,061,000, or $0.10 per basic and diluted share for fiscal year 2006. Total revenues for fiscal year 2007 were up 16% to $3,708,000 versus $3,193,000 in the prior year, primarily generated from Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

ADVERTISEMENT

Total costs and expenses in fiscal year 2007 increased to $25,618,000 from $22,276,000 for the fiscal year ended April 2006. The increase in total expenses was entirely due to an increase in research and development expenses associated with the advancement of the company's clinical and preclinical product candidates. Cost of sales related to Avid Bioservices' revenues were flat despite an increase in manufacturing revenues, and overall selling, general and administrative expenses slightly decreased from the prior fiscal year.

This current year increase in research and development expenses was primarily related to the advancement of bavituximab and Cotara® for the treatment of solid tumors and hepatitis C virus (HCV) infection. Over the past fiscal year, the company increased its expenditures in support of five separate clinical trials, including a Phase I bavituximab study for the treatment of advanced solid tumors, a Phase Ib bavituximab study in combination with chemotherapy for the treatment of advanced solid tumors, a Phase Ib bavituximab repeat dose study in patients with chronic HCV infection, and two Cotara® clinical trials for the treatment of glioblastoma multiforme, a deadly form of brain cancer. In addition, the company supported the advancement of its preclinical programs, including studies that were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in April 2007.

"This past fiscal year has been marked by significant progress in the three clinical programs that we expect to be key value drivers for Peregrine during fiscal year 2008," commented Steven W. King, president and CEO of Peregrine. "Most importantly, we successfully completed Phase lb clinical trials for our first-in-class anti-PS monoclonal antibody bavituximab for the treatment of both cancer and hepatitis C viral infection. These studies represent major milestones for the bavituximab program, with positive results in both indications showing that bavituximab appeared well-tolerated and that it demonstrated encouraging signs of anti-viral and anti-tumor activity. Successful completion of these studies has set the stage for Phase ll clinical trials."

Mr. King added, "Similarly, we laid the foundation for substantial progress in the clinical program for lead tumor necrosis therapy (TNT) agent Cotara by preparing to conduct a new trial in patients with malignant brain cancer. Our Indian clinical centers are well equipped to conduct this trial and have access to large numbers of patients with brain cancer who are eager to participate in clinical studies. We expect that positive results in this Phase ll trial would set the stage for product registration trials and eventual commercialization."

Mr. King added, "While our focus during the past fiscal year was on advancing our clinical programs, we also reported important progress in our preclinical programs. In September 2006, we reported new research showing that a fusion protein approach combining our Vascular Targeting Agent (VTA) and anti-PS technology platforms demonstrated significant potential, reducing tumor growth in animal cancer models by more than 90%. At the AACR meeting in April 2007, Peregrine's collaborators reported positive results from a number of our preclinical programs, including data indicating that bavituximab-type compounds may have potential as powerful vaccine-like agents against malignant brain cancer and also as part of immunocytokine fusion protein therapies targeted to lymphoma and other cancers. We also reported on progress in our anti-VEGF program, presenting data showing that our unique selective inhibitor was as effective as Avastin® in preclinical cancer models while having potential advantages as a result of its selectivity. Earlier in the year, a peer-reviewed publication reported that microbubbles constructed using our VTA technology can be used with widely available ultrasound systems to monitor patient response to Avastin®, identifying at an early stage which cancer patients are actually benefiting from this treatment. These developments and others highlight the depth and diversity of our preclinical programs. We currently are pursuing some of these programs on our own and are actively seeking partners to collaborate with us on others."

Mr. King concluded, "Since the start of the last fiscal year, we believe that Peregrine has made exceptional progress in advancing its three lead clinical programs towards Phase II trials and reporting progress in a number of high potential earlier stage programs. As a result of our recent financing, we now have the resources to pursue these programs aggressively in the year ahead. We believe the company has set the stage for what could be a very successful 2008 fiscal year."

At April 30 2007, the company had $16,044,000 in cash and cash equivalents. The company has strengthened its cash position to about $32,500,000 as of June 30, 2007, after taking into consideration the net proceeds received from a recent financing announced on June 28, 2007. The company believes it has sufficient cash on hand to progress its current clinical programs through at least fiscal year 2008 based on its current projections.

Corporate Highlights Since the Start of Fiscal Year 2007

-- In July 2007, Peregrine announced that it had submitted a clinical
protocol with the Drug Controller General of India for a Phase ll trial
of bavituximab in combination with chemotherapy in patients with
non-small cell lung cancer (NSCLC). Up to 21 NSCLC patients will be
enrolled initially and the study may be expanded up to a total of 49
patients if positive results are observed in the first cohort. The
primary objective of the study is to assess overall response to the
combination of bavituximab and chemotherapy; secondary objectives
include time to tumor progression, duration of response, overall
patient survival and safety parameters. This trial is expected to begin
enrolling patients later this year.
-- In June 2007, Peregrine announced commitments to purchase $22.5 million
in shares of its common stock in a registered direct offering, for net
proceeds of approximately $20.9 million. The financing did not include
warrants. Rodman & Renshaw acted as the exclusive placement agent.
-- In June 2007, Peregrine announced initiation of a new clinical trial
designed to evaluate the safety and efficacy of its TNT agent Cotara in
patients with glioblastoma multiforme, a deadly form of brain cancer.
Peregrine believes that combined positive data from this new study in
India and ongoing U.S. glioblastoma trials would provide a foundation
for advancing Cotara into Phase III product registration trials.
-- In May 2007, the company reported positive results in its Phase lb open

label cancer trial of bavituximab in combination with chemotherapy.
This trial was designed to assess the safety and tolerability of
bavituximab in combination with common chemotherapy agents in advanced
cancer patients with metastatic disease. In the trial, the safety
profile of bavituximab in combination with chemotherapy appeared
similar to that seen in advanced cancer patients undergoing
chemotherapy alone. The combination of bavituximab and chemotherapy
showed positive signs of clinical activity, achieving objective tumor
response or stable disease in 50% of the patients who were evaluable
for tumor response. Data from this study are being further analyzed to
support the initiation of Phase II cancer trials.
-- In May 2007, Peregrine announced it had filed a new clinical trial
protocol with the FDA to study bavituximab in patients co-infected with
HCV and HIV, and this study was initiated in early July 2007. The
multi-center open-label study designed to assess the safety and
pharmacokinetics of bavituximab in approximately 24 patients will
initially be conducted at Saint Michael's Medical Center under the
direction of Dr. Stephen Smith. An estimated 30% of HIV patients are
co-infected with HCV and these patients often do not respond well to
current HCV therapies.
-- At the April 2007 AACR meeting, data from multiple studies reinforced
the versatility and broad anti-cancer potential of bavituximab,
provided new preclinical data confirming the potential anti-tumor
efficacy of the company's selective VEGF inhibitors, provided
validating data for its immunocytokine fusion proteins developed using
the company's VTA technology, and highlighted the clinical potential of
Peregrine's earlier stage Vasopermeation Enhancement Agent (VEA) cancer
platforms.
-- In February 2007, Peregrine reported results from a Phase lb study of
bavituximab in patients with chronic HCV infection. The study was
designed to assess the safety, distribution and pharmacokinetic
properties of four ascending dose levels of bavituximab administered as
twice-weekly monotherapy. Bavituximab was generally safe and
well-tolerated, with no dose limiting toxicities or serious adverse
events reported. The preliminary results also indicate that bavituximab
showed positive signs of dose dependent anti-viral activity, setting
the stage for HCV combination therapy trials and further dosing
studies.
-- In October 2006 at the prestigious AASLD meeting, Peregrine reported
final results from its Phase Ia study of bavituximab in HCV patients
who had failed or relapsed after standard therapy. Bavituximab
appeared generally safe and well-tolerated and there were signs of
anti-viral activity at all dose levels tested.
-- In June 2006, Peregrine announced that had signed a definitive
agreement for the sale of 9,285,714 shares of common stock to one
institutional investor in exchange for net proceeds of $13 million.
This financing involved no warrants and no placement fees.
-- In June 2006, Peregrine reported top-line results on the effect of
bavituximab on viral RNA serum titers when administered as single dose
monotherapy in a Phase Ia study in patients with chronic HCV infection.
Bavituximab showed signs of anti-viral activity at all four dose levels
studied and it also showed evidence of a prolonged anti-viral effect.

Ich habe trotzdem nochmal etwas aufgestockt. Wenn Bavituximab und/oder Cotera Erfolg haben, ist PPHM ein tenbugger. Wenn nicht, dann sieht es allerdings duster aus. Das wird ein Langzeitinvest bis mindestens Ende 2008. Viel Glück allen Investierten!

Grüße

AMDlong

[AMDlong]

Cotara natürlich...

[funworker1]

hallo admlong,

am besten die klappe halten und nichts mehr schreiben.
interessiert sowie kaum jemanden.

[funworker1]

ist vielleicht auch gut so....

[AMDlong]

Press Release Source: Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Monday October 22, 10:44 am ET

TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a Phase II clinical protocol with the Ministry of Health of the Republic of Georgia to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer. The open label, multi-center safety and efficacy trial will begin enrolling patients pending regulatory and ethics committee approvals.

ADVERTISEMENT
click here
The new trial has a two-stage design. Up to 15 patients with metastatic breast cancer will be enrolled initially and the study will be expanded up to a total of 46 patients if promising results are observed in the first cohort. The primary objective is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in the treatment for metastatic breast cancer. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. The study is expected to enroll patients at a minimum of three clinical trial sites.

"The filing of this second breast cancer protocol continues our strategy of evaluating bavituximab in Phase II combination studies in specific cancer indications," said Steven W. King, president and CEO of Peregrine. "This study also marks our first clinical initiative in Eastern Europe, which has become a major venue for global clinical trials conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards. The sites we are working with have solid experience in conducting mid and late stage cancer trials that adhere to FDA and international standards. We have been impressed to date by the professionalism of their operations, the efficiency of their patient recruitment infrastructure and their commitment to patient welfare."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to ICH and GCP guidelines.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase ll trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase ll trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is also under regulatory review in India. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

um den Thread am Leben zu halten...

Grüße,
AMDlong

[funworker1]

ist ja klasse, wie es gestern wieder gelaufen ist.
recht gute news und der kurs geht nach süden.
aber das kennen wir ja alles schon.......

[funworker1]

What do you think about the current pps $0,50 ?

Do you have an interest of strengthen the shareprice ? Many stockholders can`t see that.

How about the future ?

When will you start the Phase 2 test of bavituximab in lung cancer patients in india ?

How about DTRA contract ?

How about the phase 2 cotara (brain cancer) tests in INDIA started 08/02/07 ?

How about the future financing ? How long will you continue to offering of shares ? Continue dilution ?

Since my last mail the stock price lost another 25%

thanks and best regards from a very upset stockholder



We believe that at the current stock price, the company is significantly undervalued and that the share price will strengthen as we report further progress on our clinical programs and other strategic inititatives in the coming months.

Management is committed to increasing shareholder value by executing on our value-driving clinical programs. Protocols have been submitted for three Phase II trials of repeat doses of bavituximab in combination with chemotherapy – one for patients with non-small cell lung cancer, and the other two for patients with metastatic breast cancer. The bavituximab anti-viral program also includes an ongoing clinical trial for patients co-infected with hepatitis C virus infection and HIV. The Cotara Phase II trial for patients with glioblastoma multiforme is also ongoing. By advancing our drug candidates through clinical trials, and selectively advancing a pipeline of innovative preclinical candidates, Peregrine believes it has the potential for a strong future. We also are in the late stages of negotiating a major federal multi-million dollar contract for our anti-viral program and anticipate initiation of coverage from a respected bank analyst shortly. Peregrine management has also been working actively with its banking team to present the company 's story to biopharmaceutical institutional investors and we expect these efforts to start to bear fruit in the coming months.

The protocol for Peregrine’s Phase II trial of bavituximab in combination with chemotherapy in non-small cell lung cancer patients has been submitted. Once regulatory approval from the Indian government is achieved, patient enrollment will begin. We understand the review process is progressing and we look forward to receiving a positive response soon.

Peregrine is in negotiations with the Defense Threat Reduction Agency (DTRA) of the Department of Defense for a multi-year contract to investigate bavituximab and other anti-PS antibodies for hemorrhagic fever virus infections. Negotiations with the DTRA are proceeding well and we are optimistic the contract could be signed before the end of the year. We will alert shareholders via press release as soon as the contract is signed.

The Cotara Phase II trial for patients with GBM in India is currently enrolling patients. We expect to report some preliminary findings from this study in the coming months and anticipate completing patient enrollment in 2008. Final study results will be reported after patient follow-up to assess how well patients respond.

At the end of July, Peregrine reported that it had over $30 million in cash and cash equivalents in the bank; there are currently no plans to do another financing. However, you should be aware that all biopharmaceutical companies still in the developmental stage need to access the capital markets from time to time to fund a portion of their clinical programs. The stock price, as discouraging as it is, is not an accurate reflection right now on the health or future prospects of Peregrine's business.

[asics01]

was treibt die letzten tage den kurs so nach oben,technische reaktion news

[asics01]

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
- New Clinical Trial Will Evaluate Anti-Tumor Activity of Bavituximab in Combination with Docetaxel -

TUSTIN, Calif., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient screening has begun in a clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in advanced breast cancer. The multi-center clinical trial is being conducted in the Republic of Georgia.

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"We are delighted that patient screening has begun in this Phase II study that provides us with an excellent opportunity to further evaluate the potential efficacy of bavituximab in combination with chemotherapy in treating breast cancer," said Steven W. King, president and CEO of Peregrine. "This trial should allow us to build on the encouraging results we observed in breast cancer patients in an earlier bavituximab combination therapy study. We look forward to learning more about bavituximab's potential in this important indication in the coming months as we advance both this study and a second breast cancer trial evaluating a different combination therapy regimen."

Tumor response in this Phase II study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct two additional Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include a second breast cancer protocol assessing bavituximab in combination with carboplatin plus paclitaxel and a non-small cell lung cancer protocol assessing bavituximab in combination with carboplatin and paclitaxel. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co- infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended July 31, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Back to top




© 2003/2008 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

PPHM maschiert unter hohen umsätzen weiter nach oben.was gibt es neues??
asics

[asics01]

Antwort auf Beitrag Nr.: 33.344.924 von asics01 am 12.02.08 17:59:31

Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer

TUSTIN, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient dosing has begun in its clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in breast cancer. The multicenter clinical trial is being conducted in the Republic of Georgia.

"We are now seeing good overall momentum in our bavituximab Phase II cancer program, and we are very pleased that our clinical colleagues in Europe have been so efficient in rapidly moving from protocol approval to trial initiation to patient dosing," said Steven W. King, president and CEO of Peregrine. "We are optimistic that all three bavituximab Phase II cancer trials will proceed well in the coming months and we look forward to reporting on our progress later this year."

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"Bavituximab represents a novel strategy for the treatment of cancer that has demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing bavituximab in combination with chemotherapy. The first bavituximab breast cancer trial is now underway and the two other trials are expected to begin soon. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Jennifer Anderson
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX

[asics01]

und wieder grün,der rohdiamant wird geschliffen

[asics01]

und wieder gehen grosse brocken in usa über den tisch

[asics01]

Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
- Cotara(R) Appears Safe and Well Tolerated in Dosimetry and Phase II Trials, with Some Patients Already Past the Expected Median Average Survival Time for This Population - - Data From Dosimetry Trial Accepted for Presentation at 2008 ASCO Annual Meeting -

TUSTIN, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today released an update from two clinical trials assessing its targeted therapy Cotara(R) in the treatment of glioblastoma multiforme (GBM), the most deadly form of brain cancer. The Cotara clinical update covers the first cohort of patients in its dosimetry trial as well as experience to date in an ongoing Phase II safety and efficacy trial. In patients treated in the studies, Cotara appears to be safe and well tolerated, with no dose-limiting adverse events. Patients who are continuing in the trials are being monitored for safety and overall survival, with several surpassing the median expected survival time for relapsed GBM patients. The recent addition of new clinical sites in both the dosimetry and Phase II trials is expected to help accelerate the pace of patient enrollment going forward. The company also announced that data from the first patient cohort in the dosimetry trial has been accepted for presentation at the 2008 ASCO Annual Meeting.

"We are encouraged by early results from these two Cotara clinical studies and look forward to presenting data from the dosimetry trial at the upcoming ASCO Annual Meeting," said Steven W. King, president and CEO of Peregrine. "In view of the short expected survival time of approximately six months in this patient population, it is promising that we have early GBM patients in these trials who have survived past the six-month timeframe, with one patient now surviving 15 months post-treatment."

The open-label Phase I dosing and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose. The study's main objectives are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In the three GBM patients enrolled in the first cohort, Cotara was safe and well tolerated, with no dose-limiting toxicities. Patients have been followed post-treatment to determine overall survival, with the first treated patient currently surviving 15 months post-treatment and the last treated patient currently surviving four months post-treatment. Dosimetry analysis indicates that Cotara was concentrated only in the tumor in these patients, and not in other organs.

Mr. King added, "With enrollment of the second patient cohort underway, we welcome Dr. William Shapiro of the Barrow Neurological Institute as principal investigator of our newest dosimetry study clinical site. Dr. Shapiro successfully participated in earlier Cotara studies and we are delighted that his center is now participating in the Cotara dosimetry trial."

"We are pleased to join the dosing and dosimetry trial of Cotara for the treatment of recurrent GBM," said Dr. William Shapiro, director, neuro oncology program; Marley chair, neurology; professor of neurology, University of Arizona College of Medicine; and Cotara principal investigator at the Barrow Neurological Institute. "GBM is a deadly disease with very poor survival prospects for relapsed patients, and improved therapies are urgently needed. We are hopeful that the encouraging survival trends seen in previous Cotara studies will be replicated in larger trials going forward, and we view this dosimetry trial as an important step on that path."

Mr. King continued, "We are also pleased to report that we have recently added additional clinical sites to the Cotara Phase II study, increasing the total participating centers from three sites to eight sites. We anticipate enhanced enrollment rates going forward, particularly in view of the quality and enthusiasm of the investigators we have recruited. We look forward to reporting further interim results from the Cotara program as we achieve additional enrollment milestones in the coming months."

The objectives of the open-label Phase II trial are to confirm the safety of the selected dose of Cotara and to obtain estimates of overall patient survival, progression-free survival and the proportion of patients alive at six months in GBM patients at first relapse. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), a technique that delivers the agent to the tumor with great precision. Patients receive brain scans at eight-week intervals post-treatment. Total enrollment in the 40-patient trial has reached the 20% completion mark. Patients who are continuing in the trials are being monitored for safety and overall survival, with the first dosed patient having reached eight months of survival post-treatment. Patient screening for the trial will continue until all 40 patients have been enrolled.

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody. This monoclonal antibody is designed to bind to a type of DNA that is exposed only on dead and dying cells. Solid tumors have many dead and dying cells at their center. Cotara's targeting mechanism enables it to home in on these cells, delivering its radioactive "payload" directly to the center of the tumor mass and thereby destroying it "from the inside out" with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), which targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that survival trends will not be replicated in larger trials and the risk that the company will experience delays in patient enrollment. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Back to top




© 2003/2008 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
-Advances Reported in All Three Clinical Programs, Including Launch of Key Bavituximab Phase II Cancer Program-

TUSTIN, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the third quarter of fiscal year (FY) 2008 ended January 31, 2008. The company reported a consolidated net loss of $6,154,000, or $0.03 per basic and diluted share, compared to a consolidated net loss of $5,025,000 or $0.03 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).

Total revenues for the current quarter increased to $1,675,000 compared to $363,000 for the comparable quarter last year, and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

Total costs and expenses increased to $8,077,000 in the third quarter of FY 2008 from $5,643,000 in the same prior year quarter. The increase was primarily related to the increase in the cost of contract manufacturing of $1,066,000 during the quarter resulting from higher reported revenues from external customers, in addition to the increase in research and development expenses of $1,034,000 associated with the advancement of the company's clinical and preclinical product candidates. Research and development expenses were $4,941,000 in the third quarter of FY 2008, compared to $3,907,000 in the third quarter of FY 2007. At January 31, 2008, the company had $20,063,000 in cash and cash equivalents compared to $16,044,000 at fiscal year end April 30, 2007.

"The past quarter was highlighted by a major milestone in our oncology program, as we dosed the first patients in a Phase II trial evaluating bavituximab in combination with chemotherapy in patients with breast cancer," said Steven W. King, president and CEO of Peregrine. "We also received regulatory approval to initiate two additional bavituximab Phase II cancer trials -- a second breast cancer study and a trial in patients with non-small cell lung cancer, a leading cause of cancer deaths worldwide. Planning for these trials is well underway and we anticipate initiating both studies next month. We also made progress in our Cotara clinical program in patients with glioblastoma multiforme (GBM), today announcing promising data from the ongoing dosimetry and Phase II trials showing that several patients are already surviving longer than the expected six-month median survival time for this patient population, with the longest surviving patient now at 15 months post-treatment. Patients who are continuing in the trials are being monitored for safety and overall survival, and we look forward to providing further updates on these trials going forward. We have also recently expanded the number of clinical sites in the Phase Il study to eight and also added a distinguished brain cancer center and experienced Cotara clinical study site -- the Barrow Neurological Institute -- to our dosimetry study in the U.S."

Mr. King added, "Our initiative to raise awareness for the bavituximab and Cotara programs in the scientific and medical communities scored gains, including an oral presentation covering the clinical experience to date in the bavituximab Phase I cancer program at Angio 2008, an oral presentation of clinical data from our Phase I bavituximab trial in hepatitis C patients at the prestigious 2007 Liver Meeting(R), a recent publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.

-- Initiated patient dosing in a Phase II combination therapy trial of
bavituximab and docetaxel in patients with advanced breast cancer
within 14 days of study initiation.
-- Received regulatory approval to begin two additional Phase II
bavituximab combination therapy trials -- one in combination with
carboplatin and paclitaxel in patients with advanced breast cancer and
another in combination with carboplatin plus paclitaxel in patients
with non-small cell lung cancer (NSCLC). Both trials are preparing to
begin enrolling patients shortly.
-- A bavituximab cancer investigator presented data at a leading
scientific meeting on anti-angiogenic agents -- the 10th Annual
International Symposium on Anti-Angiogenic Agents (Angio 2008) --
highlighting the positive clinical experience to date with
bavituximab.
-- A preclinical study published in Clinical Cancer Research confirmed
bavituximab's ability to target tumor blood vessels with excellent
specificity. The high degree of selective targeting seen in the study
provides additional evidence of bavituximab's therapeutic potential.


Bavituximab Anti-Viral Program: During the third quarter, the company continued to advance its bavituximab HCV program and presented positive data at a key liver disease meeting.

-- Added The Johns Hopkins Hospital and a private clinic in Orange
County, California as additional clinical study sites for the HCV/HIV
co-infection study.
-- Presented final results from the Phase I multiple dose HCV trial at
the prestigious Annual Meeting of the American Association for the
Study of Liver Disease that showed bavituximab was well tolerated and
demonstrated encouraging signs of anti-viral activity.


Cotara(R) Glioblastoma Program: Peregrine continued to advance the Cotara brain cancer program.

-- Added additional study sites and continued patient dosing and
follow-up in the Cotara Phase II study in patients with glioblastoma
multiforme, the most deadly form of brain cancer. Eight sites are now
open for patient enrollment.
-- Added an additional site, the Barrow Neurological Institute (BNI) in
Phoenix, Arizona, to the ongoing Cotara dosimetry and dose
confirmation clinical study. BNI also participated in a previous
Cotara Phase II clinical trial.
-- Announced positive results from the first cohort of patients treated
in the Cotara dosimetry trial and from the initial patients treated in
the Cotara Phase II trial. Cotara appeared safe and well tolerated
with no dose-limiting adverse events, with continuing patients being
monitored for overall survival. Several patients in these studies
have lived longer than the six-month expected median survival time for
this patient population.


Other Preclinical Programs:
-- Preclinical data presented at the 5th Annual International
Anti-Angiogenesis Conference confirmed that Peregrine's fully human,
selective anti-VEGF antibody R84 was as effective as Avastin(R) in
inhibiting tumor growth in a model of human breast cancer. Selective
anti-VEGF agents may have potential advantages over non-selective
approaches.


Avid Bioservices:
-- Wholly owned manufacturing subsidiary Avid Bioservices signed an
agreement with ARIUS Research to produce clinical supplies of their
lead cancer stem cell anti-CD44 antibody.
-- Avid continued to demonstrate strong revenue performance during the
third quarter of fiscal year 2008.


Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 [phone]. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling [phone], passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may experience delays in clinical trial patient enrollment, the risk that future clinical trial results may not correlate with the results of prior clinical trials and preclinical studies, the risk that Avid's revenue growth may slow or decline, the risk that future protocol submissions may not be approved, the risk that the company may not be able to monetize any of its assets, the risk that the company will not regain compliance with the Nasdaq Stock Market minimum bid price requirement by July 21, 2008, and the risk that the company will not have additional high profile scientific publications and presentations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the third fiscal quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

-financial tables to follow-



PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


JANUARY 31, APRIL 30,
2008 2007
Unaudited
ASSETS

CURRENT ASSETS:
Cash and cash equivalents $20,063,000 $16,044,000
Trade and other receivables 1,316,000 750,000
Inventories, net 2,394,000 1,916,000
Prepaid expenses and other current assets 1,140,000 1,188,000

Total current assets 24,913,000 19,898,000

PROPERTY:
Leasehold improvements 669,000 646,000
Laboratory equipment 3,756,000 3,533,000
Furniture, fixtures and office equipment 913,000 873,000

5,338,000 5,052,000
Less accumulated depreciation and
amortization (3,537,000) (3,212,000)

Property, net 1,801,000 1,840,000

Other assets 1,527,000 1,259,000

TOTAL ASSETS $28,241,000 $22,997,000



PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)


JANUARY 31, APRIL 30,
2008 2007
Unaudited
LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable $2,387,000 $1,683,000
Accrued clinical trial site fees 244,000 228,000
Accrued legal and accounting fees 390,000 392,000
Accrued royalties and license fees 124,000 337,000
Accrued payroll and related costs 858,000 874,000
Notes payable, current portion - 379,000
Capital lease obligation, current portion 17,000 17,000
Deferred revenue 1,434,000 1,060,000
Other current liabilities 1,239,000 885,000

Total current liabilities 6,693,000 5,855,000

Notes payable, less current portion - 119,000
Capital lease obligation, less current portion 17,000 30,000
Deferred license revenue - 4,000
Commitments and contingencies

STOCKHOLDERS' EQUITY:
Preferred stock-$.001 par value;
authorized 5,000,000 shares; non-voting;
nil shares outstanding - -

Common stock-$.001 par value; authorized
325,000,000 shares; outstanding -
226,210,617 and 196,112,201, respectively 226,000 196,000
Additional paid-in capital 245,982,000 224,453,000
Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $28,241,000 $22,997,000



PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


THREE MONTHS ENDED NINE MONTHS ENDED
January 31, January 31, January 31 January 31,
2008 2007 2008 2007
Unaudited Unaudited Unaudited Unaudited
REVENUES:
Contract
manufacturing
revenue $1,662,000 $347,000 $5,146,000 $1,381,000
License revenue 13,000 16,000 46,000 87,000
Total revenues 1,675,000 363,000 5,192,000 1,468,000

COSTS AND EXPENSES:
Cost of contract
manufacturing 1,289,000 223,000 3,872,000 1,247,000
Research and
development 4,941,000 3,907,000 13,665,000 11,868,000
Selling, general
and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs
and expenses 8,077,000 5,643,000 23,035,000 17,939,000

LOSS FROM
OPERATIONS (6,402,000) (5,280,000) (17,843,000) (16,471,000)

OTHER INCOME
(EXPENSE):
Interest and
other income 259,000 267,000 851,000 955,000
Interest and
other expense (11,000) (12,000) (25,000) (36,000)

NET LOSS $(6,154,000) $(5,025,000) $(17,017,000) $(15,552,000)

WEIGHTED AVERAGE
COMMON SHARES
OUTSTANDING:
Basic and
Diluted 226,210,617 195,299,586 219,497,601 191,067,145

BASIC AND DILUTED
LOSS PER COMMON
SHARE $(0.03) $(0.03) $(0.08) $(0.08)


SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Back to top




© 2003/2008 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[funworker1]

wie seht ihr die aktuelle situation ?

gehen so langsam die lichter aus oder sind die aktuellen kurse
reine kaufkurse ?

nach der letzten aktienausgabe (verwässerung um ca. 15%) von 30 000 000 neuen aktien ende juni2007, müßte wir heute ohne weitere einflüsse bei ca. 0,75 $ stehen. man kann ja auch nicht sagen, daß die nach richten in den letzten monaten eine katastrophe waren (ausnahme der contract mit der regierung).

was hat uns einen tiefstkurs von ca. 0,36$ (ca.50% minus seit der letzten aktienausgabe) bescherrt. das verstehe ich einfach nicht.

wird hier manipuliert, weil die produkte so gut sind und ein großer sich PPHM irgendwann billig unter den nagel reißen will ?
wird schon die nächste verwässerung eingerechnet ?
sind die produkte von PPHM einfach nur schlecht und nichts wert ?

PPHM ist wirklich alles in allem eine sehr seltsame geschichte.

naja... machen wir weiter bis die lichter ausgehen.
das sollte ja nicht mehr allzulange dauern.

grüße
funworker

[funworker1]

!

Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users

[asics01]

Antwort auf Beitrag Nr.: 33.729.567 von funworker1 am 26.03.08 14:37:47

bios laufen allgemein nicht gut zur zeit.ich meine dass pphm eine top pipe hat,man hat avid die geld verdienen,und einige bekannte grössen die auf deren technologie zurückgreifen.
ich verstehe den kursverlauf auch nicht,und meine manchmal dass die sturmreif geschossen werden,um billig übernommen zu werden.
ich warte mal was kommt,ist wie lotto spielen nur die chance einen hauptgewinn zu landen ist hier grösser.
asics

[asics01]

müssen die sich nicht auch solangsam gedanken wegen eines delistings machen???
asics

[funworker1]

müßte so ende juli sein

[asics01]

Antwort auf Beitrag Nr.: 33.734.114 von funworker1 am 26.03.08 20:33:13

na dann müssen sie sich aber ran halten,oder kommt ein split???

asics

[funworker1]

ich hoffe und denke, daß ein RS so schnell nicht kommen wird.
aber bei pphm ist ja bekanntlich nichts unmöglich.

[asics01]

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
-No Metastatic Lesions Were Detectable After Combination Therapy Treatment-
-Survival Time More Than Doubled in Animals Treated with Combination Therapy-
-Established Tumors Regressed by 50% After Combination Therapy Treatment-

SAN DIEGO and TUSTIN, Calif., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) shows that a mouse equivalent of Peregrine's anti-phosphatidylserine (anti-PS) vascular targeting antibody bavituximab administered in combination with the chemotherapeutic agent docetaxel demonstrated excellent signs of efficacy in a preclinical model of hormone-refractory prostate cancer. These new data confirm and extend the results of previous studies of Peregrine's anti-PS antibodies in models of prostate cancer. They were described by researchers in an oral presentation at the AACR Annual Meeting at 2:10pm PDT on April 14, 2008 in San Diego, California.

Dr. Yi Yin, a postdoctoral researcher in the laboratory of Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas, reported that in a mouse model of hormone-refractory prostate cancer, the combination of the bavituximab equivalent antibody 2aG4 and the chemotherapy drug docetaxel significantly decreased the growth of tumors, eliminated detectable metastases and prevented tumor re-growth. This increase in anti-tumor efficacy and anti-metastatic activity was achieved with no apparent increase in toxicity compared to docetaxel alone.

Specifically, in the study 2aG4 administered with docetaxel reduced primary tumor burden by 95%, an anti-tumor effect that was significantly superior to that of the individual treatments administered alone. Treatment with the combination of 2aG4 and docetaxel also reduced the metastatic spread of tumor cells. In animals treated with the combination regimen, none of the treated mice (or 0%) exhibited detectable metastatic lesions, while 100% of the mice treated with a non-specific control antibody, 67% of mice treated with 2aG4 alone and half the mice treated with docetaxel alone exhibited metastatic lesions. The combination was also superior at preventing tumor re-growth. Thirteen weeks post-treatment, tumors in animals treated with the combination regimen had regressed to less than 50% of their initial volume, while in mice treated with either therapy alone or with a control antibody, the tumors increased in size by factors of between 1.5 and 5 times. Survival time was more than doubled in animals receiving combination therapy compared to controls, and was substantially longer than the survival of animals treated with either therapy alone.

"These very promising results reinforce and extend the findings of previous preclinical studies highlighting the potential of our anti-PS antibodies in combination regimens for the treatment of prostate cancer," said Steven W. King, president and CEO of Peregrine. "We are particularly encouraged by data showing that the combination of a bavituximab equivalent and docetaxel eliminated the production of detectable metastases entirely in this model, while more than doubling the survival time of the treated animals. We are currently testing this same combination regimen of bavituximab and docetaxel in a Phase II trial in patients with breast cancer, and we look forward to potentially assessing bavituximab in combination regimens in prostate cancer in future clinical trials."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab helps mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. One of the bavituximab breast cancer trials is currently enrolling and dosing patients and the two other trials are expected to begin shortly. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Prostate cancer is the most commonly diagnosed cancer in men, accounting for 30% of all male cancers, and it is second only to lung cancer as a leading cause of cancer deaths in men. Currently, there is no cure for locally advanced or metastatic prostate cancer.

This research, which was conducted under the direction of Dr. Thorpe at UT Southwestern, was supported in part by a sponsored research agreement with Peregrine Pharmaceuticals and by a grant from the U.S. Department of Defense.

Number 2551: Yi Yin, Philip E. Thorpe. Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice, UT Southwestern Medical Center, Dallas, TX, April 14, 2008, 2:10 PM - 2:25 PM

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies, the risk that bavituximab will not provide comparable results in combination with other cancer therapies and the risk that the Company will experience delays in enrolling patients in its existing and planned clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Back to top




© 2003/2008 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[Braini]

es kommt mal wieder Bewegung in unser baby .... wenn auch auf allerniedrigstem Niveau...

[funworker1]

What do you think about the current pps $0,40 ? sometimes i think that mr king and all the others does not care a penny about the shareholders ?
Supporting the stock price in this very negative market is a challenge. Small cap biotech stocks have been particularly hard hit in the current downturn. The company is focusing on advancing its two clinical programs, which are the key value drivers that will ultimately lead to greater shareholder value. The company's programs continue to progress and we remain positive and optimistic about our future once we get past the current difficulties. Management is committed to increasing shareholder value by executing on our value-driving clinical programs.

what happens to the the bavituximab anti-viral program trial including an ongoing clinical trial for patients co-infected with hepatitis C virus infection and HIV ?
The study of bavituximab in HCV patients co-infected with HIV is ongoing, and we will provide shareholders with updates on the study when significant milestones are reached.

what pappens to the Cotara Phase II trial for patients with glioblastoma multiforme is also ongoing ? ( the last mail you said: We expect to report some preliminary findings from this study in the coming months and anticipate completing patient enrollment in 2008. Final study results will be reported after patient follow-up to assess how well patients respond.]
The Cotara Phase II trial for patients with glioblastoma multiforme is still ongoing. Again, we will provide shareholders with updates on this study as appropriate.

what dou you think of missing the timeline regarding MINIMUM BID PRICE ?
Management is continuing to assess the company's options in view of the coming Nasdaq de-listing deadline. The company's programs continue to progress and we remain positive and optimistic about our future. According to communications from Nasdaq, the delisting deadline is July 21. Please note that the company will have the opportunity to request a hearing on any delisting notice and the company would not be delisted until after the appeal process was completed.

why it! s so difficult to partner one part of the pipeline and receive an upfront payment, if the pipeline is that GOOD ?
does pphm really want to partner ?
We have consistently said that we need Phase II data to achieve the type of partnerships that recognize the value of the company's investigational drugs. Data reported to date is interim Phase II data on small numbers of patients, and while positive and suggestive of eventual success, it is not by itself sufficient to support partnering deals. We expect to have more data coming in over the rest of 2008 into 2009, which will hopefully give us the critical mass to ink the type of deal we all think is feasible.

does any BP (BIG PHARMA) want to partner ?
are bavi and .... worth to partner in the eyes of BP`s ?
are working ALL BP`s together against PPM to kill them and to receive some good phase 2 products for a penny ?
We hope to have initial bavituximab Phase II cancer data in several months’ time, with more becoming available later this year into next year. If the current Phase II trials are successful, Peregrine expects to partner with a larger pharmaceutical firm to conduct the large and costly Phase III trials needed for product approval and marketing.

what is the role of KING, SWARTZ, BOYD and all the others in this game ?
Steven King, CEO, is working to advance Peregrine’s clinical programs, and Eric Swartz serves as a member of the board of directors. Since she began working with Peregrine, Mary Boyd has been in discussions with a number of potential partners and licensers in Europe and Asia . As Peregrine continues to generate more data, Dr. Boyd has more ammunition to secure collaborations that will be lucrative for Peregrine and its shareholders. We will provide updates on Dr. Boyd's efforts when Peregrine has entered into a partnership or collaboration; providing public updates while negotiations are ongoing would threaten the success of any deal.

[funworker1]

und was sagt ihr zum kurs ? kommt freude auf !
ihr kennt ja bestimmt investorshub oder ?
hoffen auf bessere zeiten.

grüsse

[funworker1]

habt ihr bei den aktuellen kursen noch nachgekauft ?

[funworker1]

Antwort auf Beitrag Nr.: 34.888.945 von funworker1 am 28.08.08 11:45:23

wann gehen die lichter bei pphm aus ?
hat jemand eine meinung ?

[rodonko]

!

Dieser Beitrag wurde moderiert. Grund: themenfremder Inhalt

[MisterKool]

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
- Patent for Antibodies that Directly Bind to Phospholipid Targets Covers All Viral Infections and All Combination Regimens -
- Patent Issuance Follows Nature Medicine Publication Confirming the Broad Anti-Viral Potential of Anti-Phospholipid Approaches -

TUSTIN, Calif., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of serious viral infections and cancer, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. The aminophospholipid family of phospholipids, including phosphatidylserine (PS), represents a novel target for anti-viral therapies. The new patent follows publication this week of a study in Nature Medicine that supports the broad anti-viral potential of the company's anti-phospholipid platform, showing that phospholipid-targeting drugs can cure lethal virus infections in animal disease models.

"Issuance of this broad anti-viral patent significantly expands our intellectual property leadership in the field of phospholipid-targeting antibodies," said Steven W. King, president and CEO of Peregrine. "Antibodies falling under the scope of this new patent are already showing promise in preclinical studies of lethal virus diseases including hemorrhagic fever and AIDS."

The new patent's allowed claims include methods of treating a broad spectrum of viral infections, including human immunodeficiency virus (HIV), influenza, hepatitis C virus (HCV) and cytomegalovirus (CMV), using one or more anti-phospholipid antibodies that directly bind to an aminophospholipid target, either alone or in combination with other anti-viral agents. The patent also covers anti-viral immunoconjugate compositions, methods and other combinations of anti-phospholipid antibodies and anti-viral agents.

"We believe this is a significant patent in the anti-viral field and we are especially pleased at the scope of the issued claims, which reflect the broad anti-viral potential of our phospholipid-targeting antibody platform," said Dr. Shelley Fussey, vice president of intellectual property at Peregrine. "This patent further extends the breadth of our intellectual property for our anti-PS technology platform, while nicely complementing the intellectual property estate we have developed for our lead clinical stage anti-PS antibody bavituximab, which binds to PS through a different mechanism."

PS is a lipid molecule usually found on the inside of cell membranes that "flips" and becomes exposed on the outside of the membranes of virally infected cells and enveloped viruses. Exposed PS is known to be immunosuppressive and could potentially enable viruses to evade immune recognition. By masking the exposed PS, Peregrine's antibodies may block these immunosuppressive signals and allow the body to develop a robust immune response to the viral pathogen. Anti-PS antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity, an important anti-viral immune response. Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, influenza, hemorrhagic fever viruses, CMV, herpes simplex viruses and smallpox viruses.

In addition to its potent anti-viral activity in lethal viral disease models, Peregrine's anti-PS antibody bavituximab appeared safe and well tolerated with promising signs of anti-viral activity in Phase I trials in patients with chronic HCV infection. Based on these positive data, Peregrine has initiated a trial in patients co-infected with HCV and HIV, a population that in the U.S. includes about 30% of all HIV patients.

This new patent was granted to The University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended August 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

[funworker1]

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2009

- Total Revenues Rose Over 300% and Net Loss Declined 46% Quarter-Over-Quarter, with Avid Revenues Reaching a Record $5.8 Million -

- Two Additional Bavituximab Phase II Cancer Trials Met Pre-Specified Endpoints for Expansion -

- All Three Bavituximab Phase II Cancer Trials Have Now Successfully Achieved Their Initial Efficacy Milestones -

TUSTIN, Calif., March 12 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the third quarter of fiscal year (FY) 2009 ended January 31, 2009.

Total revenues for the current quarter increased 308% to $6,826,000, compared to $1,675,000 for the comparable quarter in FY 2008. The increase in total revenues primarily stems from increased contract manufacturing revenues provided by Avid Bioservices, Peregrine's wholly owned biomanufacturing subsidiary. Contract manufacturing revenues generated by Avid were $5,778,000 for the third quarter of FY 2009 compared to $1,662,000 for the comparable prior year quarter. The increase in Avid revenues reflects increased production of biological products for third-party customers during the quarter, as well as the timing of certain product shipments. In addition to Avid's contract manufacturing revenues, Peregrine also generated contract revenues during the quarter for services provided under its contract with the U.S. Defense Threat Reduction Agency (DTRA) to evaluate bavituximab for the treatment of viral hemorrhagic fever infections. For the nine months ended January 31, 2009, total revenues increased to $10,284,000, up 98% from the first nine months of FY 2008.

Total costs and expenses increased 25% to $10,060,000 in the third quarter of FY 2009 from $8,077,000 in the same prior year quarter. The increase primarily reflects an increase in the cost of contract manufacturing associated with the 248% increase in third-party contract manufacturing revenues recorded by Avid during the current quarter. During the third quarter of FY 2009, R&D expenses declined as a result of planned reductions in R&D costs associated with Peregrine's preclinical programs. R&D expenses were $4,465,000 in the third quarter of FY 2009, compared to $4,941,000 in the third quarter of FY 2008. SG&A expenses declined 19% quarter-over-quarter, from $1,847,000 in the third quarter of FY 2008 to $1,489,000 in the third quarter of FY 2009. This decrease is the result of reductions in SG&A expenses across the board, reflecting the company's focus on stringent management of all discretionary expense categories. For the nine months, total costs and expenses were virtually unchanged, rising slightly from $23,035,000 in the period ended January 31, 2008 to $23,228,000 in the comparable period in 2009.

'Peregrine has achieved significant financial successes since the start of the third fiscal quarter,' said Paul Lytle, chief financial officer of Peregrine. 'Last year we began implementing a strategy to conserve cash by controlling costs and growing revenues through our government DTRA contract and through contract manufacturing services provided to outside clients, while also continuing to advance our clinical trial programs. This strategy is clearly producing results, as demonstrated by the three-fold increase in our third quarter revenues, reflecting the growing volume of biomanufacturing business at our Avid subsidiary and work performed under our contract with the DTRA. At the same time, we continued to achieve significant reductions in non-essential R&D costs and SG&A expenses, reducing our net loss in the quarter by almost half compared to last year. We believe these successes in effectively deploying our capital resources while achieving important operational milestones are helping to provide a sound foundation for our progress going forward.'

Peregrine reported a consolidated net loss of $3,332,000, or $0.01 per basic and diluted share, compared to a consolidated net loss of $6,154,000, or $0.03 per basic and diluted share for the same prior year period, a decrease of 46%. The consolidated net loss for the nine months declined 24%, from $17,017,000 in the period ended January 31, 2008 to $12,915,000 in the comparable period in 2009. The declines in net loss are the result of increases in the company's total revenues combined with decreased costs in many areas of Peregrine's business.

At January 31, 2009, the company had $10.9 million in cash and cash equivalents.

'Over the past few months we achieved a number of noteworthy advancements in our development efforts, including promising data from our ongoing Phase II bavituximab clinical studies and a high profile publication for our bavituximab anti-viral program,' said Steven W. King, president and CEO of Peregrine. 'Last year we initiated three separate Phase II clinical trials designed to evaluate bavituximab in combination with standard cancer therapies. These trials have a two-stage design that requires achievement of pre-specified efficacy endpoints to expand enrollment beyond the pilot stage. With our recent announcement that our Phase ll trials in breast cancer and non-small cell lung cancer (NSCLC) had achieved these criteria, all three of our bavituximab Phase ll cancer trials have now decisively met their respective pre-established endpoints for expanding enrollment.'

Mr. King added, 'In addition to advancing our clinical programs, during the third quarter we also received significant validation for our anti-PS anti-viral technology platform through the publication in the highly regarded journal Nature Medicine of impressive preclinical data evaluating bavituximab and related anti-PS antibodies for the treatment of lethal virus infections. The recent clinical results from our bavituximab cancer program and the Nature Medicine article were widely reported in both industry periodicals and in the mainstream media, raising awareness for our bavituximab program and heightening interest from potential development partners. We anticipate that these ongoing clinical studies will continue to generate additional newsflow and interest over the coming months as we prepare for a number of important scientific presentations and publications.'

Mr. King concluded, 'This is an exciting time for Peregrine and we look forward to continuing to advance the programs that we believe will build value in our company while providing potential new treatment options for patients confronting life threatening diseases.'

Recent Operating Highlights

Bavituximab Anti-Cancer Program

Peregrine reported progress in all three Phase II trials in the bavituximab cancer program:

-- Initiated patient dosing in Stage B of the Phase II trial of bavituximab in combination with docetaxel in advanced breast cancer patients.

-- Completed patient enrollment in Stage A of the Phase II trial of bavituximab in combination with carboplatin and paclitaxel in patients with advanced breast cancer. Reported positive initial results from this trial that exceeded the pre-specified endpoint for proceeding to Stage B, with seven of 14 evaluable patients achieving an objective response according to RECIST criteria. Of note, this 50% response rate in patients with locally advanced or metastatic breast cancer was observed after only two 28-day treatment cycles. Patients in the trial are eligible for up to six cycles.

-- Completed patient enrollment in Stage A of the Phase II trial of bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer. Reported positive initial results from this trial that exceeded the pre-specified endpoint for proceeding to Stage B, with seven of 17 evaluable patients achieving an objective response according to RECIST criteria after four 21-day treatment cycles out of a possible six cycles.

Bavituximab Anti-Viral Program

The company continued to advance the bavituximab anti-viral program and received major validation for its anti-PS anti-viral platform:

-- Reported publication of data in Nature Medicine that supports the broad anti-viral potential of Peregrine's anti-PS antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

-- Ramped up activities under its multi-year contract with the U.S. DTRA to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers.

Other Developments

-- Entered into a loan agreement for up to $10 million in funding to finance ongoing development efforts.

-- Avid Bioservices expanded its biomanufacturing capabilities with the installation of two Thermo Scientific HyClone Single-Use Bioreactors, which further enhance Avid's ability to meet the growing demand for its cell culture production services. Data from Avid's experience with these units and other advanced technology was highlighted at a recent industry conference.

SOURCE Peregrine Pharmaceuticals, Inc.

Source: PR Newswire (March 12, 2009 - 7:00 AM EDT)

News by QuoteMedia

[funworker1]

hat noch jemand in den letzten 4-5 monaten nachgekauft, um seinen
einstand zu verbilligen ?

sieht doch eigentlich ganz gut aus. steht und fällt natürlich mit den
news, die so bis ende mai anstehen.

gruß
funworker

[funworker1]

wahrscheinlich sind auch fast alle in dem amerikanischen forum ihub unterwegs, denn da spielt die musik.

[funworker1]

Cowen and Company 29th Annual Health Care Conference
March 18, 2009 9:30 AM - 10:05 AM

Speaker: Steven King, President and Chief Executive Officer, Peregrine Pharmaceuticals, Inc.
Location: The Boston Marriott Copley Place
Boston, MA
US

© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved

[funworker1]

kann jemand sagen wo gädda geblieben ist ?

[funworker1]

ist gut zu wissen, daß sich fast keiner für PPHM
interessiert, umso größer ist die chance, weil ja bekanntlich
99% an der börse falsch liegen.

[funworker1]

Targeted Cancer Therapies (X8)
March 30, 2009 8:00 AM PT

Speaker: Philip E. Thorpe, University of Texas Southwestern Medical Center

Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies


© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved

[asics01]

Antwort auf Beitrag Nr.: 36.765.525 von funworker1 am 13.03.09 21:57:23

hallo funworker
ich war auch lange zeit in PPHM drin,bin aber zum glück rechtzeitig raus.momentan juckt es wieder rein zu gehen,aber ob PPHM die nächsten jahre finanziell überlebt???
bis zu einer möglichen zulassung ist ja noch ein langer weg.

asics

[funworker1]

hallo asics01,

ich bin noch voll dabei mit schnitt von 0,35 $ je stück und
bin sehr hoffnungsfroh, daß sie finaziell noch die kurve
kriegen. wenn die endergebnisse der 3x phase2 tests so positiv
sind, wie sie sich bisher zeigen, gibt es bestimmt externe geldgeber, ohne den kurse weiter zu verwässern. zudem sollte bei positiven ergebnissen auch der kurs anziehen. nicht zu vergessen natürlich auch die tochter AVID.

also ich bin froh, das ich hier dabei bin. bis ende mai wissen wir
wohl wohin peregrine steuert.

gruß
funworker

[funworker1]

achso, nächster delisting termin ist irgendwann im juni,
nach bisher mehreren verlängerungen durch die nasdaq.

[funworker1]

© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved

[asics01]

Antwort auf Beitrag Nr.: 36.769.139 von funworker1 am 15.03.09 11:54:43

was wurde überhaupt aus 2C3,weißt du dass???

asics

[funworker1]

ne, weiß ich nicht.

[funworker1]

wer lust hat die conference heute im web zu verfolgen, kann sich hier anmelden.

http://ir.peregrineinc.com/eventdetail.cfm?EventID=66301

[asics01]

ich habe ein bischen zeit mitgebracht,und bin seit heute wieder dabei

[funworker1]

diese entscheidung wirst du wohl mittel- langfristig nicht bereuen
ich versuche meine stücke so lange zu halten, bis peregrine
übernommen wird oder die lichter ausgehen.

jetzt sind es noch 6 wochen bis zur ASCO conference.
Ich wünschte es wäre schon soweit, dann wüßte wir zu 100%,
wo mit PPHM stehen.

LICHT AUS oder FLUTLICHTANLAGE AN

[asics01]

Antwort auf Beitrag Nr.: 36.986.100 von funworker1 am 17.04.09 09:31:09

pphm und avi,es gibt schlechteres.es müssen mal ein paar news kommen dann wird sich schon was bewegen.die werden wohl alles geben, auch um das delisting herumzukommen.

FLUTLICHT an

[funworker1]

wenn hier das flutlicht angeschaltet wird,
brennen erstmal sauber die sicherungen durch

hast du so eine bißchen den hype um dndn mitbekommen ?

ich möchte das ja nicht schlechtreden, aber diese bewertung
mit fast 2 000 000 000 $ ist der absolute witz. 1 medikament für eine krebsform. wenn da nur irgendein störfeuer von der FDA kommt, wie schon erlebt, klappt das alles wieder zusammen. aber bisher natürlich ein traum für die anleger.

pphm steht da auf einem viel breiteren fundament mit ihrer pipeline und nicht zu vergessen AVID und DTRA.

[funworker1]

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial


- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response -

- Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall -

TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), today announced that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel showed that 11 of 17 evaluable patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) achieved an objective tumor response according to RECIST criteria, after completing the maximum six treatment cycles. The company also reported that patient dosing is underway in the expansion stage of the trial, which will enroll an additional 28 patients for a total of 49 patients overall.

"We are very pleased to see these additional objective tumor responses in this difficult-to-treat cancer following the full regimen of six treatment cycles of bavituximab and chemotherapy," said Steven W. King, president and CEO of Peregrine. "These updated results build on the impressive data we reported after only four treatment cycles, which had already exceeded the pre-defined number of objective tumor responses needed to expand the trial to the larger cohort."

Mr. King added, "The tumor response data to date from this trial compares favorably to published studies with current standard-of-care lung cancer treatments, and we are looking forward to seeing results from the entire study. With dosing now underway in the expanded patient cohort, we expect to resume the brisk pace of enrollment achieved in the first cohort, with the goal of completing patient enrollment around mid-year. We intend to provide further updates as patient treatment and follow-up continue in the coming months."

The primary objective of the multi-center, open-label Phase II study is to assess the overall response rate to bavituximab with carboplatin and paclitaxel. In the trial's Simon two-stage design, 21 patients with previously untreated locally advanced or metastatic NSCLC were initially enrolled and 17 of these patients were deemed evaluable. In this initial cohort, 11 of the 17 evaluable patients achieved an objective tumor response by the time that treatment with the combination of bavituximab, carboplatin and paclitaxel was completed. Eight of the 11 objective tumor responses were confirmed by at least one repeat scan no less than four weeks after the criteria for response were first met.

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in men and women in the U.S. and is the leading cause of cancer deaths. It estimates that in 2008, there were approximately 215,020 new cases of lung cancer in the U.S. and an estimated 161,840 lung cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.


Source: Peregrine Pharmaceuticals, Inc

[asics01]

Antwort auf Beitrag Nr.: 37.002.033 von funworker1 am 20.04.09 14:22:26

diese news hat auch keinen vom hocker gehauen,alles beim alten

[funworker1]

das kennen wir ja schon
macht mich aber nicht wirklich nervös

[funworker1]

wir sind weiterhion auf dem richtigen weg und irgendwann
wird sich das auch im kurs zeigen

[Jano57]

TUSTIN, Calif., May 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today provided an update on progress in the company's clinical program for Cotara(R), a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that patient enrollment in the final cohort of a second Cotara GBM trial, a dose confirmation and dosimetry study, is nearing completion and that interim data from this trial has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009.

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from time of disease recurrence.

In the ongoing Phase II safety and efficacy trial, over half of the 40 planned GBM patients have been dosed with Cotara and patient follow-up is continuing. Screening for the anticipated final patient in the dose confirmation and dosimetry trial is underway and patient follow-up in that trial also is continuing. Data from this trial continues to support the superior targeting properties of Cotara and the resulting accumulation of high doses of radiation specifically in the tumor.

"We are encouraged at the continuing progress in the Cotara clinical program, with screening for the anticipated final patient in the dosing and dosimetry trial now underway, more than half of the planned GBM patients enrolled in the Phase II trial, and acceptance of our oral presentation at the upcoming Society of Nuclear Medicine Annual Meeting," said Steven W. King, president and CEO of Peregrine. "Patients have tolerated the Cotara regimen well and we continue to see longer-term survivors among the treated patients, consistent with our experience in previous Cotara clinical studies."

Overall, Cotara has been administered to a total of more than 115 patients with brain, colon or liver cancer. Promising data from these studies support Cotara's ability to specifically target solid tumors and its anti-tumor activity, as well as its acceptable safety profile.

Mr. King added, "We continue to actively explore partnering opportunities and options for expanding the accessibility of Cotara to GBM patients in the U.S. and other territories, to ensure continued development of this drug candidate that we believe may offer a positive treatment option for patients with this devastating disease."

The primary objective of the open label, multi-center Phase II trial is to confirm the maximum tolerated dose of Cotara in GBM patients at first relapse. Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patients alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), a technique that delivers the agent to the tumor with great precision. Brain scans are administered at eight-week intervals post-treatment. Cotara has been generally well tolerated with an acceptable safety profile in clinical studies completed to date.

The main objectives of the open label Phase I dosing and dosimetry study at U.S. brain cancer centers are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression free survival and the proportion of patients alive at six months following Cotara administration. Dosimetry data presented at the 2008 ASCO Annual Meeting showed that Cotara delivered 100-fold more radiation to the tumor as compared to other organs. Expanded data from this study has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting on June 16, 2009 in Toronto, Canada.

KURS aktuell 0,94$

[Massel]

!! NEWS !!

PEREGRINE BRICHT AUS !!

PRE MARKTET:
Last: $ .90 Pre-Market
High: $ .95
Pre-Market
Volume: 187,625 Pre-Market
Low: $ .859



ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer



- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center -


- New Study Complements Ongoing Bavituximab Plus Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results -


TUSTIN, Calif., June 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the ASCO Research Foundation has awarded one of its 2009 Career Development Awards to David Gerber, MD, of the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab and chemotherapy in patients with advanced lung cancer. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects.


This new study will supplement Peregrine's Phase II clinical trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). In the first cohort of this trial, 11 of 17 evaluable NSCLC patients, or 64.7%, achieved an objective tumor response according to response evaluation criteria in solid tumors (RECIST). Enrollment of an additional 28 NSCLC patients is ongoing.


"We are delighted that the ASCO Research Foundation has selected Dr. Gerber's study for this prestigious award that nicely complements our ongoing Phase II NSCLC trial, which has already shown very promising results," said Steven W. King, president and CEO of Peregrine. "This clinical study should help us to better understand the biological effects of this new class of immunotherapeutic agents and generate data that will help guide the future clinical development and use of bavituximab."


Dr. Gerber, assistant professor at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, will receive a three-year award totaling $200,000 to support his original research, A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer. These competitive awards are available to promising physician researchers who are full-time faculty members in a clinical setting at an academic medical center.


Bavituximab is also currently being tested in combination with chemotherapy in two Phase II trials in advanced breast cancer. Preliminary positive results from one of these trials were the subject of an oral presentation at the 2009 ASCO Annual Meeting.


About Phosphatidylserine (PS)-Targeting Immunotherapies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at www.peregrineinc.com.


About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.


Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of the Phase II trial will not be consistent with the objective tumor responses experienced in the first stage of the Phase II trial. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]



SOURCE Peregrine Pharmaceuticals, Inc.

[Massel]

Pre-Market
Last: $ .92 Pre-Market
High: $ .95
Pre-Market
Volume: 290,337 Pre-Market
Low: $ .859

[Massel]

Das kann ja heute heute werden:

Pre-Market
Last: $ 1.01 Pre-Market
High: $ 1.02
Pre-Market
Volume: 1,000,324 Pre-Market
Low: $ .859


Close war gestern 0.84, also momentan schon +20% im Premarket.

gruß
massel

[Pokerlui007]

leider am 1$ abgeprallt!

Aktuell bei 0,94$....bei 0,90$ geh ich auch rein!

[Massel]

yep, das ist halt alles Spekulation...

gruß
massel

[Moneymaker123]

Das geht aber wohl eher wieder runter.
Pre Market hat nichts gebracht!

[Massel]

Antwort auf Beitrag Nr.: 37.364.062 von Moneymaker123 am 10.06.09 15:45:09

die ersten 1.5 Std. sind meistens zum....., mdenke aber das die 0.90 halten werden....

[Pokerlui007]

sieht wohl nach nem gap close aus...0,91$ aktuell

[3ckv]

mal den Tag nicht vor dem Abend loben

[Massel]

Antwort auf Beitrag Nr.: 37.364.145 von Pokerlui007 am 10.06.09 15:51:47

na, biste drinn ??

[Massel]

jetzt gehts auch bei Novavax ab.. (NVAX) RT 2.98 bei sattem Volumen....

[Massel]

RT 0,95

[Massel]

die Profi schlagen wahrscheinlich kurz vor 22 Uhr nochmal zu,
dann sollte der US-Dollar fallen.....

bis nachher
massel

[funworker1]

es wäre wirklich wünschenswert, wenn wir uns, bei nach wie vor guten news, weiter die zähne an der 1$ marke ausbeissen. 1$ ist so ein heftiger widerstand, da sollen bullen und bären sich erstmal ordentlich bekämpfen, um dann zu einem wahnsinns sprung anzusetzen.

aber bekanntlich kommt es meißt anders.... siehe DNDN

[funworker1]

ein buy limit auf 0,65$ zu legen wäre wohl auch nicht das dümmste... wenn der gap close noch kommen sollte

[3ckv]

ich weiss nicht, ob ich mit Verlust hier raus soll??

[funworker1]

auf gar keinen fall.... lass dich nicht verrückt machen..
pphm ist gerade im ersten gang..... bleib ruhig... schua dir mal den 10 jahres chart an, in verbindung mit der fundamentalen lage.

[funworker1]

wo liegt dein KK ? ca. 0,90 -1 $ oder ?

[3ckv]

Antwort auf Beitrag Nr.: 37.381.926 von funworker1 am 12.06.09 15:52:03

bin zu spät rein .99

[funworker1]

mensch, das ist doch vollkommen OK.....

[funworker1]

ich will hier natürlich nicht den eindruck erwecken, daß pphm der absolute highflyer wird und AVASTIN von roche in den schatten stellt. aber die news der letzten monate zeigen den richtigen weg. wenn jetzt noch die finanziellen nöte gelöst werden, ohne verwässerung neues geld kommt, muss uns nicht bange sein.

charttechnisch sieht doch alles super aus oder ?

es bleibt wirklich unglaublich spannend

funworker

[funworker1]

schaffen wir nächste woche den anfang der nasdaq regeln oder mehr ?

glaube nicht und....

[3ckv]

vielleicht heute?

[funworker1]

bin nicht davon überzeugt...1$ ist so ne harte nuss.
aber schön wärs....

[Pokerlui007]

RT 0,87$ was ist los!!??

[3ckv]

Mann oh Mann

was läuft ab????

all Meine Bios sind am fallen

[Pokerlui007]

meine auch!!

hab hier zu 0,85$ nochmal nachgelegt...Ende des Jahres lachen wir bei 2$ über Kurse von jetzt!!

[3ckv]

Antwort auf Beitrag Nr.: 37.412.329 von Pokerlui007 am 17.06.09 16:57:04

ja, dann geb ich ne Runde aus

ich bin am überlegen, ob ich schmeissen soll

[3ckv]

weiss jemand, was mitdiesem Wert los ist???

[asics01]

!

Dieser Beitrag wurde moderiert. Grund: Beschwerde durch Firma liegt w:o vor

[3ckv]

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
----Affitech Gains Exclusive Worldwide Rights to Develop and Commercialize New Anti-VEGF Antibodies-- ----Peregrine to Receive Upfront and Research Fees, Potential Milestone Payments and Royalties from Affitech--

TUSTIN, Calif. and HORSHOLM, Denmark, July 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) and Affitech A/S (Nasdaq OMX: AFFI) today announced that they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, Affitech will license exclusive worldwide rights to develop and commercialize products under Peregrine's selective anti-VEGF intellectual property portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration. Under the license agreement, Affitech will be responsible for future preclinical and clinical development and potential product commercialization. Peregrine will receive an upfront payment, research fees and future milestone payments potentially totaling in the double-digit millions (US$). Peregrine will also receive royalties on any future sales and a share of sublicensing revenues. Additional financial terms were not disclosed.

Announcing the transaction, Steven W. King, president and CEO of Peregrine, said, "This licensing agreement with Affitech is an excellent opportunity for both companies. The selective anti-VEGF antibodies we have been jointly developing with Affitech hold significant clinical promise and we are pleased that Affitech will now have the opportunity to develop and commercialize them on behalf of both companies. This agreement will allow us to realize positive short-term cash flow and at the same time maintain an interest in the significant upside potential of the anti-VEGF program. This agreement fits very nicely with our announced corporate strategy to monetize and advance our preclinical pipeline through partnerships or licensing agreements, while focusing our R&D efforts on advancing our later-stage clinical programs highlighted by our bavituximab Phase II cancer program, which is already generating promising clinical data."

Commenting on the licensing agreement, Dr. Achim Kaufhold, chief executive officer of Affitech, said, "Using advanced phage display technologies, Affitech successfully identified fully human, potent and selective anti-VEGF antibodies as part of a previous research and development collaboration with Peregrine. As a result of the recently completed reverse acquisition of Pharmexa, Affitech has now added product development expertise to its drug discovery capabilities. We are therefore delighted now to have acquired the exclusive worldwide development and commercialization rights for this exciting program."

Anti-VEGF therapy has become a standard part of treatments for many different types of solid tumors. According to projections of some market analysts, sales of anti-VEGF antibodies are expected to exceed $10 billion by 2015. The fully human and selective anti-VEGF monoclonal antibody, r84, which is the most advanced candidate in Peregrine's anti-VEGF antibody program, targets the cancer-promoting growth factor VEGF. Data presented at IBC's 5th Annual International Anti-Angiogenesis Conference in 2007 showed that r84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a number of models of human cancers, including a mouse model of human breast cancer. r84 is distinctive because it selectively blocks VEGF from binding to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents such as r84 may have safety and efficacy advantages over non-selective approaches. In addition, the fully human nature of the r84 antibody minimizes the risk of an immune response against the drug itself, thereby lessening the potential for immunological side effects and neutralization of the treatment effect. As a fully human antibody, r84 may also have better pharmacokinetic properties in patients.

About Affitech A/S

Affitech A/S is an antibody research and development company. It was formed recently by a reverse merger of Norway, Oslo-based Affitech AS with Pharmexa A/S, a Danish biotech company. The merged company has developed several proprietary technology platforms that constitute a highly productive, fully human, antibody discovery engine. Based on its proprietary technologies and know-how, Affitech has built a pipeline of promising human antibody candidates for internal development or co-development with collaboration partners. The focus of the newly expanded company is to pursue both research and clinical development of antibody therapeutic products. Further information can be found at www.affitech.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not receive some or all of the future milestone payments or royalties, the risk that the program does not have significant upside potential and the risk that sales of anti-VEGF antibodies do not achieve the levels projected by some market analysts. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

Quelle: Peregrine Hompage

[3ckv]

bereits +10%

geil

[asics01]

Antwort auf Beitrag Nr.: 37.623.362 von 3ckv am 22.07.09 15:31:11

und wie immer nach guten news,ein kurzes aufbäumen um dann wieder abzutauchen.so isse die pphm

asics

[Fruehrentner]

Bristol-Myers kündigt Übernahme von Medarex an

New York (aktiencheck.de AG) - Der US-Pharmakonzern Bristol-Myers Squibb Co. (ISIN US1101221083/ WKN 850501) kündigte am Mittwochabend die Übernahme des Biotechnologie-Spezialisten Medarex Inc. (ISIN US5839161016/ WKN 883040) an.

Demnach lässt sich Bristol-Myers Squibb die Übernahme von Medarex insgesamt rund 2,4 Mrd. Dollar kosten, wobei Medarex über einen Netto-Barmittelbestand von 300 Mio. Dollar verfüge. Im Rahmen der Vereinbarung sollen die Aktionäre des Biotechnologiekonzerns jeweils 16,00 Dollar je Aktie in bar erhalten.

Durch die Übernahme will sich der Pharmakonzern vor allem im Bereich Immun-Onkologiue verstärken, zumal Medarex in diesem Segment über eine vielversprechende Produktpipeline verfüge.

Die Aktie von Bristol-Myers Squibb notierte zuletzt bei 20,29 Dollar, während die Anteilsscheine von Medarex zuletzt bei 8,40 Dollar notierten. (23.07.2009/ac/n/a)

erschienen am 22 23.07.2009 um 10:18 Uhr

http://newsticker.welt.de/?module=smarthouse&id=918758



MEDAREX ist ebenfalls stark bei monoklonalen Antikörpern.

PEREGRINE somit ebenfalls ein Übernahmekandidat?

[asics01]

Antwort auf Beitrag Nr.: 37.630.874 von Fruehrentner am 23.07.09 13:10:02

wundert mich sowieso dass da bis jetzt noch kein grosser zugelangt hat,waren ja bis vor kurzem recht billig zu haben.

asics

[asics01]

wann startet die rakete??demnächst knallt es, ich hoffe aber doch dass es kein blindgänger ist

[asics01]

ist denn PPHM in sachen schweinegrippe auch aktiv ???

asics

[funworker1]

hi asics01,

ob hier was mit schweinegrippe geht weiß ich nicht.
aber mir ist PPHM sowieso ziemlich egal momentan. ich habe wirklich andere sorgen. geld sollte mir echt scheißegal sein...... ich habe meinen stopp jetzt fuer meine ganze pos. von 164kstck auf 0,41 $ gesetzt und werde nicht mehr hinschauen;-). immer diese börsen, die einem das leben zur hölle machen....................................................

LG
fw

[asics01]

Antwort auf Beitrag Nr.: 37.749.505 von funworker1 am 10.08.09 22:08:33

dir gehört ja der halbe laden
aber wenn du mal die umsätze der letzten tage verfolgt hast ,was da die ganze zeit für brocken über den tisch gingen (gehen),könnte man meinen da positioniert sich wer.
pphm wird mit aller gewalt unten gehalten,aber irgendwann funktioniert das nicht mehr,dann rauscht es im gebälck.

asics

[asics01]

Antwort auf Beitrag Nr.: 37.749.505 von funworker1 am 10.08.09 22:08:33

SL 0,41$??? soweit runter wirds doch wohl nicht mehr gehen.
pphm steht auf der abschussrampe,darf aber noch nicht starten
geheimnissvolle mächte haben da noch ihre hände im spiel

asics

[asics01]

bin mal gespannt wie weit pphm noch herunter gezogen wird???

[funworker1]

Antwort auf Beitrag Nr.: 37.820.292 von asics01 am 20.08.09 18:22:56

hallo asics,

bis 0,41 und dann startet die rakete

ne, mal im ernst. wir sind jetzt 4 wochen ohne news, das kommt ganz selten im jahr vor. im september gibt es bestimmt mehr action.
der reversesplit ist ja wohl auch wieder mit im spiel....

mal schaun

funworker

p.s. wer hatte ende mai mi dem run von 0,55 auf fast 1,2 gerechnet ? ich nicht !

[asics01]

Antwort auf Beitrag Nr.: 37.820.550 von funworker1 am 20.08.09 18:55:23

p.s. wer hatte ende mai mi dem run von 0,55 auf fast 1,2 gerechnet ? ich nicht (und zurück)

[asics01]

Antwort auf Beitrag Nr.: 37.670.601 von asics01 am 29.07.09 16:22:33

schon ein paar tage her der bericht,aber dann ist bavituxmab bestimmt auch bei der schweinegrippe anwendbar oder ???
kurs 1,57$ 2006 und heute???

asics


24.05.2006 – Autor: C. Huber




Die Aktien des Biotechnologieunternehmens Peregrine Pharmaceuticals gehen vorbörslich wegen der Nachricht über Erfolge bei dem Versuch der Herstellung von Abwehrstoffen gegen die Vogelgrippe durch die Decke. Wie das Unternehmen am Mittwoch mitteilte, hat der antivirale Wirkstoff des Unternehmens, Bavituximab, in Laborversuchen bei befruchteten Hühnereien die Reproduzierung des H5N1-Erregers vollständig blockiert. Die ersten Daten der Versuche werden auf dem American Society for Microbiology in Orlando veröffentlicht.

Peregrine Pharmaceuticals legen vorbörslich um 11% auf 1,57 Dollar zu

[asics01]

NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
- Two-Year Research Grant will Support Evaluation of New Anti-PS Antibodies as Broad-Spectrum Agents to Treat Viral Hemorrhagic Fever Infections -
- New NIAID-Funded Research Complements Peregrine's Ongoing TMTI Research Contract to Evaluate Bavituximab as a Potential Therapy for Viral Hemorrhagic Fevers -

TUSTIN, Calif., Aug 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections. Anti-PS antibodies work through a unique mechanism that allows the body's own immune system to recognize and attack virus infections. Previously published preclinical data and ongoing research support the potential of anti-PS antibodies for the treatment of VHF infections. The objective of the newly funded research is to evaluate a panel of new fully human anti-PS antibodies with different binding and functional properties as potential second-generation treatments.

The new studies complement Peregrine's ongoing research evaluating its lead anti-PS antibody bavituximab and an equivalent fully human antibody for the treatment of VHF, which is classified as a significant biodefense threat. In 2008, Peregrine was awarded a five-year research contract worth up to $44.4 million by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI). In previous preclinical studies funded by NIAID, bavituximab demonstrated encouraging anti-viral activity as a potential treatment for hemorrhagic fevers.

"PS is a highly specific, host-derived target that becomes exposed on cells when they are infected by a broad variety of viruses," said Dr. Thorpe, professor of pharmacology at UT Southwestern. "As a result, anti-viral approaches targeting PS have potential as broad-spectrum agents effective against a range of viral infections, including VHF and other emerging virus pathogens. This grant from NIAID will enable us to conduct studies in VHF models to assess the anti-viral potential of a panel of fully human anti-PS antibodies. We expect the results will be useful for the development of anti-PS therapies for viral hemorrhagic fevers and also will enhance our basic understanding of anti-PS mechanisms in the treatment of virus infections."

Dr. Thorpe is a pioneer in the field of anti-PS biology and its application to anti-viral and anti-cancer therapeutics. The PS-targeting technology developed by Dr. Thorpe and his colleagues at UT Southwestern is exclusively licensed to Peregrine.

"The research we are conducting under our TMTI contract to assess bavituximab and an equivalent human antibody against VHF infections is already generating promising results, and Dr. Thorpe's work under this new NIAID grant dovetails very nicely with that research," said Steven W. King, president and CEO of Peregrine. "The NIAID grant will allow our research collaborators to expand our existing VHF research to the evaluation of new PS-targeting antibodies that could extend the potential of our anti-PS platform. We expect it will result in greater understanding of the anti-viral mechanisms of our anti-PS technology platform that should be valuable for the development of new therapies against VHF as well as other serious viral infections."

Bavituximab is currently being assessed in a clinical trial in patients co-infected with hepatitis C virus (HCV) and HIV. Bavituximab and Peregrine's other PS-targeting antibodies may have anti-viral potential in a wide range of other virus infections including influenza, cytomegalovirus and biodefense targets such as Ebola, Yellow Fever and Punta Toro viruses. Peregrine's collaborators currently evaluating the anti-viral potential of its PS-targeting platform include researchers affiliated with Duke University, Harvard University, UT Southwestern, the NIH, Utah State University, the Southwest Foundation for Biomedical Research, the University of Texas Medical Branch at Galveston and other institutions. Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

The fully human anti-PS antibodies being used in Dr. Thorpe's NIAID research were developed by Affitech A/S in collaboration with Peregrine.

About Phosphatidylserine (PS)-Targeting Anti-Viral Agents

PS is a lipid molecule normally found on the inside of cell membranes that "flips" and becomes exposed on the outside of the membranes of enveloped viruses and virally infected cells. Exposed PS enables viruses to evade immune recognition and dampens the body's normal responses to infection. By masking the exposed PS, bavituximab and other PS targeting antibodies may block these effects and allow the body to develop a robust immune response. Anti-PS antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity, an important anti-viral immune response. Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, HCV, influenza, hemorrhagic fever viruses, CMV, herpes simplex viruses, respiratory syncytial virus, measles and members of the smallpox and rabies virus families. In addition to its potent anti-viral activity in lethal viral disease models, Peregrine's PS-targeting antibody bavituximab appeared safe and well tolerated with promising signs of anti-viral activity in Phase I trials in patients with chronic HCV infection. An article by Soares et al. discussing the broad anti-viral potential of bavituximab was published in the December 2008 edition of Nature Medicine. For more information on the anti-viral mechanisms of PS-targeting agents, see the Anti-PS Technical Background--Anti-Viral at www.peregrineinc.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved

[asics01]

wer pphm kennt wird aber wissen dass auch diese news verpuffen wird,
aber vielleicht irgendwann????????????

asics

[asics01]

BAVITUXIMAB könnte mal der MEGAHAMMER werden

[asics01]

Antwort auf Beitrag Nr.: 37.858.722 von asics01 am 26.08.09 19:39:36

wir sind schon wieder unten,wie vermutet

[asics01]

Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
-Current Clinical Director of Massachusetts General Hospital and Professor at Harvard Medical School Adds Clinical Trial Design and Drug Development Expertise-

TUSTIN, Calif., Aug 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical director of Massachusetts General Hospital (MGH) Cancer Center, chief of hematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished 25-year career at the National Cancer Institute (NCI), including serving as scientific director and director of the Division of Cancer Treatment. He has received numerous honors and awards, including the U.S. Public Health Service's Distinguished Service Award for his leadership in the development and approval of paclitaxel (Taxol(R)), a mainstay of current cancer therapy.

Dr. Chabner joins a group of advisors that have been assisting Peregrine in planning for the next stage of clinical trials for its bavituximab and Cotara(R) cancer programs. Bavituximab is currently being evaluated in three Phase II clinical trials in patients with advanced breast and lung cancer. Encouraging preliminary data from ongoing bavituximab clinical trials was presented at the 2009 Annual Meeting of the American Society of Clinical Oncology.

"Bavituximab's novel mechanism that enables the patient's immune system to attack tumors more effectively combined with its natural synergy with chemotherapy make it an intriguing and promising new approach to treating solid tumors," said Dr. Chabner. "The early clinical data on bavituximab is encouraging and I look forward to assisting Peregrine as they advance the bavituximab cancer program into later-stage trials in a number of indications."

Dr. Chabner has contributed to important advances in cancer drug research and clinical trial design during a distinguished career that spans four decades. Dr. Chabner is a member of the National Cancer Advisory Board and is editor-in-chief of the journal The Oncologist. He graduated with honors from Yale College and received his M.D. degree from Harvard Medical School.

"The increased attention bavituximab and Cotara have been receiving from oncology researchers is exemplified by the fact that Dr. Chabner, globally recognized as a leading cancer researcher and key opinion leader, has chosen to become actively involved in helping to guide our clinical programs," said Steven W. King, president and CEO of Peregrine. "We believe Dr. Chabner's contributions will be very valuable as we design the next set of bavituximab clinical studies that are critical to advance the program through later-stage clinical trials."

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may not have sufficient financial resources to support the additional contemplated later-stage trials. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Jennifer Anderson
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved

[funworker1]

und ascis kommt jetzt was ? sieht doch ganz gut aus

ich fahre morgen für 2 wochen zu meiner freundin nach peru, wäre natürlich der hammer, wenn in dieser zeit die sicherungen durchbrennen würden

beste grüße
funworker

[asics01]

Antwort auf Beitrag Nr.: 37.900.798 von funworker1 am 02.09.09 11:36:41

funworker ich halte die stellung,lass es dir gut gehen in peru.
alles wird gut,nach diesen umsätzen die letzten wochen war (ist)das nur eine frage der zeit bis es hier knallt.

asics

[asics01]

vielleicht ist das der grund der guten vorbörse,hoffentlich fällt der kurs nicht gleich wieder zusammen.
zur zeit nur gute news, PPHM ziiiiiieeeehhhhhh



Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara(R) for Treatment of Brain Cancer
-Interim Data from Lead Clinical Site in Ongoing Phase II Study Evaluating Cotara in Patients with Recurrent Glioblastoma Shows It is Generally Well Tolerated with Encouraging Signs of Efficacy-
-Recurrent GBM Patients Treated with a Single Dose of Cotara as Monotherapy Had Interim Median Recurrence-Free Survival of 33 Weeks and Median Overall Survival of 41 Weeks-
-Expected Survival for Patients with GBM is Approximately 24 Weeks from Time of Disease Recurrence-

BOSTON, Mass. and TUSTIN, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being presented today at the XIV World Congress of Neurological Surgery Annual Meeting by Dr. Deepak Gupta, assistant professor of neurosurgery at the All India Institute of Medical Sciences (AIIMS) in New Delhi on behalf of the Cotara study team that includes Drs. A.K. Mahapatra, Ashish Suri and C.S. Bal.

Dr. Gupta will present interim data for 10 recurrent GBM patients at first relapse treated at AIIMS as part of an ongoing 40 patient Phase II clinical trial. Eight males and two females with a mean age of 51 years received a single intratumoral infusion of Cotara. Currently, follow-up duration ranges from between seven to over 73 weeks with an interim median recurrence-free survival of 33 weeks and an interim median overall survival of 41 weeks. Expected survival for patients with GBM is approximately 24 weeks from time of disease recurrence. Based on this interim data, the study authors conclude that Cotara appears to be feasible, tolerable and has encouraging signs of efficacy in recurrent GBM patients.

"This interim data from our Phase II trial suggests that Cotara has the potential to be a valuable new therapy for patients with glioblastoma, a devastating disease with few treatment options," said Dr. A.K. Mahapatra, professor of neurosurgery at AIIMS and principle investigator on the Cotara study. "Our experience to date with Cotara shows that it is feasible to administer and is quite well tolerated in these very ill patients. Most importantly, Cotara has demonstrated promising signs of efficacy. We look forward to enrolling more GBM patients in the Cotara trial over the coming months and to further assessing the experience of the patients treated to date."

The Cotara Phase ll multi-center open label study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The primary objective of the trial is to confirm the maximum tolerated dose of Cotara in GBM patients at first relapse. Secondary objectives include estimates of overall patient survival, progression-free survival and the proportion of patients alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), a technique that delivers the agent to the tumor with great precision. Brain scans are administered at eight-week intervals post-treatment. The study is being conducted according to internationally accepted ICH and GCP guidelines.

"The interim data being presented today for the GBM patients treated at AIIMS supports the meaningful signs of clinical activity seen in prior Cotara trials as measured by median overall survival," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "Previous clinical data presented earlier this year has shown the ability of Cotara to specifically deliver high doses of radiation to GBM tumors, resulting in significant anti-tumor effects. The early data from this ongoing Phase II study is providing further evidence that Cotara's ability to target tumors with great specificity may provide clinical benefit to patients with this devastating disease. We look forward to completing enrollment and reporting data on the entire trial as soon as possible."

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some recurrent GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately 24 weeks from time of disease recurrence.

Overall, Cotara has been administered to a total of more than 125 patients with brain, colon or liver cancer. Promising data from these studies support Cotara's ability to specifically target solid tumors and its anti-tumor activity, as well as its acceptable safety profile.

The presentation, Efficacy of Intratumoral Radioimmunotherapeutic Agent Cotara in Recurrent GBM: Initial Experience with 10 Cases, is being presented today at 2:54 pm EDT at the XIV World Congress of Neurological Surgery Annual Meeting at the Hynes Convention Center in Boston, MA.

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. In addition to the Phase II trial now underway in India, a dosimetry and dose confirmation trial in glioblastoma patients at leading U.S. academic brain cancer centers is nearing completion. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from larger trials will not be consistent with results experienced in earlier trials. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Jennifer Anderson
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved

[asics01]

das ging heute aber wieder flott runter, geht immer schneller,RESPEKT

[dottore]

TUSTIN, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.


Avid generated manufacturing revenues of $2,070,000 for the first quarter of FY 2010, compared to $1,193,000 for the comparable prior year quarter, an increase of 74%. The increase in Avid revenues reflects increased manufacturing services provided to third-party customers during the quarter. In addition to manufacturing revenues, Peregrine generated revenues from services provided under its contract with the U.S. Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI) to evaluate bavituximab as a potential broad-spectrum treatment for viral hemorrhagic fever infections. Government contract revenues were $4,671,000 for the first quarter of FY 2010, compared to $324,000 for the prior year quarter when the government contract work had just begun.


Total costs and expenses in the first quarter of FY 2010 were $8,940,000, compared to $6,677,000 in the first quarter of FY 2009, an increase of 34%. Costs of contract manufacturing, which increased to $1,073,000 in the first quarter of FY 2010 from $903,000 in the prior year quarter, were directly driven by the increase in Avid revenue. Research and development (R&D) expenses increased to $6,074,000 in the first quarter of FY 2010, compared to $4,0
'/>"/>


SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.

[asics01]

heute gibt es wieder richtig feuer,pphm wird gerade wieder eingestampt.mann oh mann was für ein scheiss spiel ist das,gute news auf gute news und immer gleich wieder abverkauft.
aber auch da werden sich hoffentlich mal ein paar kräftig die finger verbrennen alles nur eine frage der zeit.

[funworker1]

asics,

insgeheim habe ich auch auf mehr gehofft. aber was soll
von quartalszahlen bei einem biotechwert schon für ein schub kommen.
so langsam sollten wir das spiel doch kennen oder ?

das was den kurs nachhaltig über 1$ bringt (weißt du sicherlich auch)

1.) gute- sehr gute bavi ergebnisse P2-
2.) dito COTARA
3.) dito Viral bavi

und entscheidend (deke ich) in verbindung mit 1, 2 oder 3 ein partnering. then, only the sky is the limit.

guter kursverlauf wäre doch: wir bleiben noch etwas unter 1$, explodieren dann mit guten SEHR GUTEN NEWS auf 2$, bleiben hier eine ganze zeit ( 1-2$, ca. 3-12 monate) und packen dann den hammer aus wenn die ersten guten ergebnisse aus P3 kommen. aber bekanntlich, erstens kommt es anders und 2tens als man denkt

lg
funworker

[asics01]

Antwort auf Beitrag Nr.: 37.914.632 von funworker1 am 03.09.09 20:55:11

da sind höhere mächte im spiel,der kurs geht dahin wo die hohen herren es möchten.egal mein ek liegt bei 0,32€ und ich habe ein paar stück das kannst du mir glauben.

[funworker1]

sehr schön

so soll es ein asics, wenn es knallt machen wir ein faß auf !

[asics01]

Antwort auf Beitrag Nr.: 37.915.033 von funworker1 am 03.09.09 21:40:43

die spielchen gehen weiter,da wird auf teufel komm raus gedrückt.
ich lege die jetzt mal in die untere schublade,und schau mal in ein paar monaten wieder rein.

[asics01]

was mich mal interessieren würde,wer drückt die ganze zeit und wer kauft da immer solche grossen blöcke weg

[asics01]

Avid Bioservices Becomes U.S. West Coast Partner of Boehringer Ingelheim's Global Production Alliance Network for Biologic Contract Manufacturing Services
- Partnership Expected to Expand Customer Base for Both Companies While Providing High-Yield Biologic Production Capabilities to Avid Clients -

TUSTIN, Calif., Sept 21, 2009 /PRNewswire via COMTEX News Network/ -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, and Boehringer Ingelheim, a global leader in biopharmaceutical development and manufacturing, today announced that the two companies have entered into a global strategic production alliance agreement. Under the terms of the non-exclusive agreement, Avid will become an approved member of Boehringer Ingelheim's global Production Alliance Network PAN Biologics(TM).

"With its location on the West Coast of the U.S. and a reputation for quality and innovation, Avid Bioservices is well positioned to play an important role as a strategic partner in our global Production Alliance Network," said Professor Dr. Rolf G. Werner, senior vice president of Boehringer Ingelheim's Corporate Division Biopharmaceuticals. "The Network complements our worldwide strategic manufacturing capabilities with strong regional partners providing process development and clinical supply manufacturing capacity and expertise. We believe this partnership benefits both our partners and our customers, and we look forward to working with the Avid team."

The Production Alliance Network program is set up to provide the partners' customers with a broader range of contract services. The integrated concept offers access to Boehringer Ingelheim's high expression BI HEX(R) technology, Avid's proven competence and flexibility in process development and cGMP manufacturing along with preferred access to Boehringer Ingelheim's large-scale commercial manufacturing facilities. Compatible technology platforms at Avid Bioservices and Boehringer Ingelheim support a flexible approach and will facilitate seamless technology transfers throughout the development, scale-up, clinical and commercial scale production phases.

"With this agreement, Avid joins an elite group of Boehringer Ingelheim strategic biologics manufacturing partners located in biotech clusters around the world," said Christopher Eso, vice president of business operations of Avid Bioservices. "This agreement represents an important element of Avid's overall growth strategy and is a testament to the quality of services the Avid team provides to its clients. We expect it will extend both companies' customer offerings by capitalizing on the distinctive capabilities of each."

Mr. Eso continued, "In fiscal year 2009, Avid increased its production capacity and booked record revenues as a result of a substantial increase in demand for our services. We now look forward to additional growth of our client base through our new relationship with Boehringer Ingelheim."

"We believe this selection as the sole U.S. West Coast biologics manufacturer in Boehringer Ingelheim's global Network reflects Avid's cGMP production capabilities, our outstanding inspection and regulatory history, our proven capacity to produce clinical grade material and our excellent industry reputation," said Richard Richieri, senior vice president of bioprocess development and manufacturing at Avid Bioservices. "We expect this partnership to shorten the product development time for our customers while providing them access to proprietary high yield production technology and the option of a smooth transfer to Boehringer Ingelheim for their larger scale production needs."

Avid Bioservices is a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM).

About Avid Bioservices

Avid Bioservices provides a comprehensive range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid manufactures cGMP commercial product, as well as clinical supplies for all phases of clinical trials. The company's comprehensive range of cGMP services includes cell banking, stability testing, clinical product manufacturing and purification, bulk packaging, final product filling and regulatory support. Avid also provides a variety of process development activities, including cell line optimization, analytical method development and product characterization. The company has over 10 years of manufacturing experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes. For more information about Avid, visit www.avidbio.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is one of the leading companies for industrial customer manufacturing of biopharmaceuticals by offering the entire production technology chain in development and production at its biopharmaceutical facilities in Biberach (Germany) and in Vienna (Austria). The large-scale manufacturing sites deliver biopharmaceutical products like therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody fragments and plasmid DNA. The Biberach site is specialized in highly efficient mammalian cell culture systems with yields well above industry standard in animal component free media. The Austria site offers high-expression in bacteria and yeast with exceptionally high productivities using proprietary systems. In the plasmid DNA manufacturing arena Boehringer Ingelheim in Austria has set the standard and supplies early to late-stage clinical trials with gene-therapeutics and DNA vaccines for its international clients. For more information please visit www.boehringer-ingelheim.com/biopharm.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., that provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
Avid Bioservices Media
Chris Eso GendeLLIndheim BioCom Partners
Vice President, Business Operations Barbara Lindheim
[phone] [phone]

SOURCE Avid Bioservices, Inc.

http://www.avidbio.com/
Copyright (C) 2009 PR Newswire. All rights reserved


Back to top




© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
- Data from Initial Cohort in Phase II Study Evaluating Bavituximab with Carboplatin and Paclitaxel in NSCLC Shows Progression-Free-Survival of 6.5 Months, which Compares Favorably with Historical Data Using Chemotherapy Alone -
- Patient Enrollment Now Completed in Entire 49-Patient NSCLC Study -

TUSTIN, Calif., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria. Recent analysis from the 21-patient cohort now shows the median progression-free-survival (PFS) for these patients was 6.5 months, which compares favorably with the PFS range of 4.2 to 4.5 months reported in a similar patient population receiving carboplatin and paclitaxel as a single agent in NSCLC trials that were the basis for the design of the ongoing bavituximab study. Peregrine also reported that it has completed enrolling the total of 49 NSCLC patients planned for this study.

"The PFS data we reported today along with the objective tumor response data previously reported for the first set of patients in this study are very encouraging," said Steven W. King, president and CEO of Peregrine. "Based on these results we have already begun designing our next studies in NSCLC, where we believe bavituximab has considerable promise. We will continue to assess patients enrolled in the now-completed expansion cohort over the coming months and look forward to reporting results from the full 49-patient study population."

The primary objective of the multi-center, open-label Phase II NSCLC study is to assess the overall response rate to bavituximab with carboplatin and paclitaxel. In the trial's Simon two-stage design, 21 patients with previously untreated locally advanced or metastatic NSCLC were initially enrolled, and 17 of these patients were deemed evaluable. In this initial cohort, 11 of the 17 evaluable patients achieved an objective tumor response by the time that treatment with the combination of bavituximab, carboplatin and paclitaxel was completed. These initial results exceeded the pre-specified endpoint needed to expand the trial, which then enrolled an additional 28 patients to reach the planned study total of 49 patients.

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as a monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in men and women in the U.S. and is the leading cause of cancer deaths. It estimates that in 2009, there will be approximately 219,440 new cases of lung cancer in the U.S. and an estimated 159,000 lung cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By masking PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab is being tested in combination with chemotherapy in three Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in all of these trials were encouraging, with objective tumor response rates that compare favorably to chemotherapy alone. Enrollment in the three trials is now complete and patient treatment and follow-up are continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy and the risk that the results of the subsequent stage for this trial will not be consistent with the results of the first stage. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved


Back to top




© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

PPHM kommt einfach nicht in die gänge

[funworker1]

das wird schon

ich habe schonmal gewinne mitgenommen. habe gestern
600 stck. von meinen 164Kstck. zu 0,70 $ verkauft. 100% gewinn

aber der rest wird erst bei 5-8$ oder 11$
aber vielleicht auch bei 0,000000 $ verkauft

wer weiß

[funworker1]

asics,

hast du dir mal die überarbeitete website von PPHM angeschaut ?
macht einen ganz guten eindruck.

[funworker1]

super wäre auch, daß wenn PPHM bei 8 steht, der eur wieder
parität zum dollar hätte. das wäre das tüpfelchen auf dem iiiiiii

[asics01]

Antwort auf Beitrag Nr.: 38.134.081 von funworker1 am 07.10.09 18:47:52

bei 11$ gehe ich in rente

[asics01]

Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
- New Anti-Viral Research Group to Coordinate and Expand Externally Funded Collaborations Assessing Peregrine's Broad-Spectrum PS-Targeting Antibodies as Potential Anti-Infective Therapies, Vaccines and Topical Preventatives -
- Peregrine's PS-Targeting Anti-Viral Platform Is Being Studied at More than a Dozen Leading Research Institutions with Over $60 Million in Potential Funding Already in Place from TMTI, NIAID, the Gates Foundation and the UC System -
- Broad-Spectrum PS-Targeting Antibodies Have Shown Promise in Life-Threatening Infectious Diseases Including HCV, HIV, CMV, Viral Hemorrhagic Fevers and Leishmaniasis -

TUSTIN, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has established a new Anti-Viral Research Group in its R&D organization. The new group has responsibility for coordinating, expanding and leveraging the company's multiple external collaborations already underway or planned to assess the potential utility of Peregrine's phosphatidylserine (PS)-targeting antibody platform for the prevention and treatment of a broad range of serious infectious diseases, including viral hemorrhagic fevers (VHF) and other biodefense threats, HIV, influenza, cytomegalovirus (CMV), leishmaniasis and malaria.

Peregrine's broad-spectrum PS-targeting antibodies are being assessed in anti-infective applications by more than a dozen leading research institutions. These collaborative efforts include studies assessing PS-targeting antibodies as potential therapeutics for HIV, VHF and CMV; studies assessing anti-PS antibodies as vaccines or vaccine adjuvants for the prevention of HIV and other infectious diseases; and studies of PS-targeting antibodies as potential topical microbicides against sexually transmitted diseases such as HIV and herpes viruses. Peregrine and its collaborators have already secured over $60 million in research funding to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections, and Peregrine researchers believe there is significant potential for additional applications of the technology in other infectious diseases.

"We are establishing our new Anti-Viral Research Group to maximize the clinical and commercial potential represented by the increasing interest from major research institutions and private and public funding agencies in studying our PS-targeting antibody platform as a novel approach to the prevention and treatment of a range of serious infectious diseases," said Steven W. King, president and CEO of Peregrine. "A growing body of published scientific research confirms that PS plays an important role in the development of many serious viral diseases, as well as in protozoan-caused illnesses such as malaria and leishmaniasis, conditions that impact the lives of millions of people worldwide each year. We believe that our PS-targeting antibody platform has the potential to address the large commercial markets represented by these diseases and to significantly impact the well-being of people around the globe. As a result, we see many opportunities to both optimize our current collaborations and to obtain new funding and support from additional external sources. This is the focus and mission of the Anti-Viral Research Group, and we are confident that it will be successful in identifying additional resources to help advance our PS-targeting anti-infective programs in the near and mid-term."

PS, a lipid molecule normally found only on the inside of cell membranes, becomes exposed on the outside of the membranes of certain viruses and virally infected cells. A rapidly growing body of published scientific research confirms that exposed PS is directly involved in the pathogenesis of many serious infectious diseases. Exposed PS enables viruses to evade immune recognition and dampens the body's normal responses to infection. By masking the exposed PS, PS-targeting antibodies are believed to block these effects, allowing the body to develop a robust immune response to the pathogen. Peregrine's PS-targeting antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity. Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, influenza, herpes simplex viruses, hemorrhagic fever viruses, measles and members of the smallpox and rabies virus families. Scientists have also found that PS is exposed in certain infections caused by protozoan organisms, such as malaria and leishmaniasis.

Bavituximab, which is Peregrine's most advanced PS-targeting antibody, is currently being studied in a clinical trial for the treatment of patients co-infected with HCV and HIV. Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity.

Peregrine's anti-PS antibodies are also generating positive data in preclinical HIV studies conducted by researchers from leading universities and medical research institutions in the U.S. and U.K. with funding from the Bill and Melinda Gates Foundation and the National Institutes of Allergy and Infectious Diseases (NIAID). These studies have yielded promising results that support the potential of PS-targeting agents for use as therapeutics, in vaccines and as topical microbicides, an especially promising application urgently needed in the effort to help women avoid infection with HIV and other sexually transmitted diseases such as herpes viruses and chlamydia. In addition, collaborators are also investigating the utility of PS-targeting antibodies against CMV infections and leishmaniasis, a protozoan disease that attacks people and cattle in tropical regions, with devastating effects on both health and economic well-being.

Under a major biodefense initiative funded by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI), bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million. This contract, which is funding work at Peregrine and at several collaborating institutions, was awarded based on positive data from earlier studies in animals infected with VHF that was funded by a previous grant from NIAID. This work is going well, and Peregrine intends to report early results at an upcoming biodefense conference. NIAID also recently awarded a new VHF grant to Peregrine's collaborators at UT Southwestern Medical Center.

Dr. Amy Brideau-Andersen will be directing the new Anti-Viral Research Group. Before joining Peregrine in 2006, she played an important role in the discovery and development of novel anti-viral drugs at Valeant Pharmaceuticals and at Maxygen, Inc. Dr. Brideau-Andersen completed her post-doctoral training in virology at The Scripps Research Institute. She earned B.S/M.S. degrees from Worcester Polytechnic Institute and was awarded a Ph.D. in molecular biology from Princeton University.

"As a virologist, I am excited about the opportunity to lead this initiative," said Dr. Brideau-Andersen. "PS is a novel host-derived target that is present in many different viral infections. It has the potential to help harness the body's own immune defenses to combat infection while avoiding the problems of resistance that have limited the utility of many anti-viral agents. We look forward to working proactively with both our current collaborators and with the many scientific and medical organizations that are coming to us seeking to learn more about this important new approach."

Peregrine's collaborators currently include researchers affiliated with Duke University, Harvard University, UT Southwestern Medical Center, the National Institutes of Health, Utah State University, the Southwest Foundation for Biomedical Research, the University of California at Irvine, Northwestern University, the University of Texas Medical Branch at Galveston and other institutions in the U.S., U.K., and Brazil.

A scientific publication by Drs. Melina Soares and Philip Thorpe and colleagues discussing the broad anti-viral potential of bavituximab and other PS-targeting antibodies received wide attention when it was published in the December 2008 edition of Nature Medicine.

Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's work on viral hemorrhagic fevers is funded by the Transformational Medical Technologies Initiative (TMTI) under contract HDTRA1-08-C-0003.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the Company will not receive the full $44.4 million awarded under the TMTI program. the risk that bavituximab will not achieve broad-spectrum anti-viral effects and the risk that PS-targeting antibodies will not be less susceptible to viral mutations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved







© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[funworker1]

neuester stand





© 2003/2007 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

Antwort auf Beitrag Nr.: 38.154.841 von funworker1 am 11.10.09 13:07:05

hey funworker

trotz allem liegt noch langer steiniger und wohl stessiger weg vor pphm und uns.
mal eine top news bezüglich cotara oder verpartnerung, dann geht es vielleicht mal ein wenig hoch.
gefährlich wird es jetzt da wir am freitag die 0,70$ unterschritten haben.ich werde auch bei weiter fallenden kursen nicht mehr nachlegen.
ich vermute als nächstes kommt der rs splitt

asics

[asics01]

der abwärtstrend ist intakt,0,50$ sind nicht mehr weit. wenn der gesamtmarkt abgibt wird es wohl recht schnell gehen.
tja wär ich bei 0,80$ raus hätte ich einen schönen schnitt gemacht.

[funworker1]

klar, hätte ich bei 1$ irgendwas meine pos verkauft, wäre jetzt ein guter betrag auf meinem konto.

asics, spar dir das ! bleib dabei bis das ding verkauft wird oder die lich(t)er ausgehen.

[funworker1]

momentan scheint es, als würde alles gegen pphm laufen.....
aber...

[asics01]

Antwort auf Beitrag Nr.: 38.179.927 von funworker1 am 14.10.09 22:13:02

reine nervensache,oder doch nur schrott????

[funworker1]

das überrascht mich doch schon, daß du von schrott sprichst

[funworker1]

asics, hast du eigentlich so ne mitteilung hinsichtlich der abstimmung reverse split etc., von deinem broker oder von PPHM direkt erhalten ?

ich nämlich zum wiederholten male nicht. bin wahrscheinlich
mit meiner stückzahl ein zu kleines licht oder ?

[asics01]

funworker schau hin heute (bis jetzt)grün ich glaubs nicht
ne habe auch nichts erhalten,woher hast du die news bezüglich rs splitt??
mit dem schrott war nur aus der laune heraus,weil da gedrückt wird ohne ende

asics

[funworker1]

investorshub.....

hier z.b. proxy vote und incentive plan

I expect it will be more productive for long investor interests to get the proxy vote uncertainty resolved sooner rather than later so PPHM can get on with running the company. I will be voting my shares by this weekend. I haven't been home when those nice calls from PPHM came through, but they have called at least four times. It is time for PPHM (and me) to get on with things so the proxy vote issues are resolved.

[funworker1]

rs split sind keine news, nur stimmrechte. das war meine frage

[funworker1]

bis jetzt grün ist gut ! wenn es doch nicht so ernst wäre

[asics01]

Antwort auf Beitrag Nr.: 38.185.994 von funworker1 am 15.10.09 17:01:05

da kommen die letzten wochen nur gute news,und was passiert ???es wird draufgehauen auf teufel komm raus. der markt hat immer recht.
da wird halt wieder eine sau durch die gassen getrieben.
bis jetzt grün,meinst du das bleibt heute so???ich habe da meine zweifel.
asics

[asics01]

schon wieder rot, geil

[funworker1]

super, wir haben grün geschlossen

[funworker1]

zu den 3 phase2 cancer trails wird es wohl bis ende des jahres auch nicht mehr so viele news geben. einzig der trail bavi+docetaxel for breast cancer sollte bald news bringen.


Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
--Preliminary Data from This Trial to be Presented at ASCO-
--First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment-
May 4, 2009

Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
-Data Update Shows 71% of Evaluable Patients in the Trial's First Stage Achieved Objective Tumor Responses-
-Patient Enrollment is Open in the Trial's Second Stage-
Oct 21, 2008

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
- Pre-Specified Primary Efficacy Endpoint Met in Stage 1 of Two-Stage Study -
- 100% of Evaluable Patients to Date Continue to Show Objective Tumor Response or Stable Disease -
July 2, 2008

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
- First 15 Patients Are Enrolled and Dosing With Bavituximab Plus Docetaxel Combination Regimen is Underway -
April 29, 2008

Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Feb 12, 2008

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Jan 29, 2008

Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Nov. 16 2007

Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
TUSTIN, Calif., Oct. 22 2007


Copyright © 2009 PR Newswire. All rights reserved

[asics01]

Antwort auf Beitrag Nr.: 38.192.448 von funworker1 am 16.10.09 12:57:31

bei 0,55$ bin ich weg,also recht bald wie es ausschaut

[asics01]

Antwort auf Beitrag Nr.: 38.192.186 von funworker1 am 16.10.09 12:31:18

aber nach dem rasanten anstieg gestern,musste es heute natürlich eine korrektur geben

[funworker1]

ich bin bei 0,00000 oder bei verkauf weg.

[asics01]

Antwort auf Beitrag Nr.: 38.195.616 von funworker1 am 16.10.09 18:23:39

wenn das in dem tempo weiter so abwärts geht hast du deine 0,00001 balde erreicht
spass beiseite wer zieht pphm so runter?? gründe ???

asics

[funworker1]

würde ich gerne wissen, welche penner das sind. die lachen sich wahrscheinlich kaputt über uns. bei dem volumen ist es wohl auch nicht sehr schwer den kurs zu manipulieren. man kann es nur immer wieder sagen, uns fehlen news, die entweder die finanzen in ein ganz neues licht rücken. ich denke am besten mit einer sehr guten partnerschaft mit einem großen konzern. lieblingsspruch von KING we are in talks. soll endlich mal sagen mit wem sie in talks sind und wann diese scheiß gespräche beendet sind (von der so hoch gelobten mary boyd hört man auch überhaupt nichts) oder aber der knaller kommt durch die abschließenden phase2 breast cancer ergebnisse oder beides zusammen. und asics wenn dann ein plus von 100% im tagesverlauf wieder abverkauft wird, dann, so muss ich mich korrigieren, bin ich wohl auch weg und mit meiner geduld am ende.

alle news der letzten wochen waren gut,
aber eben keine richtigen knaller

[funworker1]

am 26.10.2009 ist ja auch das delisting date

[asics01]

Antwort auf Beitrag Nr.: 38.196.462 von funworker1 am 16.10.09 20:05:43

es gibt demnächst den rs split,das ist so sicher wie das amen in der kirche.
nur wann???

[funworker1]

rs split 1:5 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

[asics01]

Antwort auf Beitrag Nr.: 38.197.043 von funworker1 am 16.10.09 21:21:54

musste ja kommen ,bin mal gespannt wie das der markt aufnimmt???
wird wohl weiter runter geprügelt,was solls ich schau mir das bis 0,55$ an und dann geh ich.

asics

[funworker1]

wann hatten wir das letzte mal so einen long trendtag...
aber keine bange, wird morgen wieder abverkauft.
so kennen wir doch pphm

[asics01]

Antwort auf Beitrag Nr.: 38.209.231 von funworker1 am 19.10.09 21:33:49

[asics01]

Antwort auf Beitrag Nr.: 38.209.231 von funworker1 am 19.10.09 21:33:49

wird wohl so sein,sie werden wohl schon wieder draufhauen

[funworker1]

:O:O

war schon ein wenig ironie dabei

asics, wie schaffen das noch

[funworker1]

close 4.00 pm 3.40$

[funworker1]

morgen ist HIV konferenz in paris und am donnerstag shareholdermeeting

[asics01]

Antwort auf Beitrag Nr.: 38.209.648 von funworker1 am 19.10.09 22:24:36

wenigstens zum neubeginn grün

[asics01]

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
- 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles -
- Tumor Response Data Compares Favorably with Published Results in a Similar Patient Population Receiving Docetaxel Alone -

TUSTIN, Calif., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.

Joseph Shan, vice president of clinical and regulatory affairs at Peregrine commented, "We are very encouraged by the initial results reported today for the full 46 patients enrolled in the bavituximab plus docetaxel Phase II trial. The tumor response data reported in this study exceeded the tumor response data for docetaxel alone that was used as the benchmark for the design of this study. With these positive initial data in hand, we and our expert advisors believe that this combination regimen warrants further clinical evaluation, and we are now assessing possible trial designs for future studies."

The primary objective of the multi-center, open-label Phase Il study is to assess the overall response rate to bavituximab and docetaxel. In this trial's Simon two-stage design, 15 patients were initially enrolled in the study followed by an additional 31 patients after the pre-specified primary efficacy endpoint for expanding the study was met, bringing the total to 46 patients. Initial data from the first set of 15 patients in the study was reported in an oral presentation at the 2009 ASCO Annual Meeting. Recent analysis showed the median progression-free-survival (PFS) of patients enrolled in the initial 15-patient cohort of the study was 7.4 months, a promising early result. Patient follow-up in the trial is continuing.

"The data released today continues to reinforce the positive results seen across the five cancer trials to date assessing the potential of bavituximab in different treatment combinations across multiple tumor types," said Steven W. King, president and CEO of Peregrine. "We believe this data in aggregate shows the broad potential of this novel therapeutic compound for the treatment of solid tumors. We look forward to reporting further results from our ongoing bavituximab studies and to providing more details on future clinical development plans as they are finalized over the coming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab acts by binding to externalized PS on tumor blood vessels and inducing immune cell-mediated destruction of these blood vessels. It also restores the immune system's ability to recognize and respond to tumor cells by blocking PS-mediated immunosuppression. Bavituximab is being tested in combination with chemotherapy in Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in these trials have been encouraging, with objective tumor response rates that compare favorably to chemotherapy alone.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that that the rate of objective tumor response for future trials will not be consistent with the objective tumor response experienced in the Phase II trials and the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:
GendeLLindheim BioCom Partners
Investors Media
[e-mail] Barbara Lindheim
[phone] [phone]

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com
Copyright (C) 2009 PR Newswire. All rights reserved


Back to top




© 2003/2009 Peregrine Pharmaceuticals Inc., All Rights Reserved Disclaimer | Safe Harbor

[asics01]

Antwort auf Beitrag Nr.: 38.223.722 von asics01 am 21.10.09 16:35:55

nach diesen news heute nur -5%?????da geht doch noch was

[asics01]

hallo funworker
bis wann sind denn unsere shares gesperrt???
hoffentlich kriegen wir die los bevor wir den 1$ wieder haben
asics

[funworker1]

ja, ist doch alles so gekommen wie erwartet, nur mit etwas verzögerung. die news haben schließlich den ausschlag für das minus gegeben. wir kennen das ja, aber ärgern tuts mich dennoch immer.

ich bin jetzt doch wieder am überlegen noch ein wenig zuzukaufen,solange wir uns unter 200 000k marketcap bewegen

sperrfrist ? sollte es eigentlich keine geben.

verkauft du mir einen teil deiner aktien ?

[asics01]

Antwort auf Beitrag Nr.: 38.238.923 von funworker1 am 23.10.09 10:56:20

bin bei consors,meine waren bis heute gesperrt.
wenn der preis stimmt kannst du welche haben.mich nervt diese drückerei furchtbar,zum glück waren meine bis heute gesperrt,sonst hätte ich gestern im frust alle geschmissen.
heute sieht die welt wieder anders aus,aber nachkaufen werde ich nicht mehr.

asics

[funworker1]

und asics, wie ist das befinden ?

bei PPHM muss man wirklich nerven wie drahtseile haben.
ob wir eines tages für diese geschundenen nerven entlohnt werden...

ich bleibe dabei! das ding verlässt mein konto nicht unter 1kkk market cap .....

schönen sonntag noch

funworker

[funworker1]

ich denke wir können uns schlafen legen...
soviel wird bis ende jahre an news nicht mehr kommen.
alles andere wäre eine riesen überraschung.
weiter die nerven halten

[funworker1]

wir müssen uns wohl noch 1-2 jahre gedulden bis die übernahme kommt oder wir pleite sind. keine lange zeit, wenn man schon seit 8 jahren dabei ist.

[funworker1]

ich werde jetzt nochmal 600 stück nachlegen...
eine market cap von 130kk ist doch sehr gering.
ich werde die chance nutzen.
chance/risiko ist sehr gut.

[Fruehrentner]

Peregrine Receives US Patent For Phospholipid-Targeting Antibodies

Published: 04-Nov-2009

The new patent covers peregrine's lead PS-targeting antibody bavituximab and similar agents for the treatment of all viral infections

Peregrine Pharmaceuticals has received US Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies. It also includes Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

The company said that the new patent covers compositions and methods of treating virus infections using bavituximab and similar antibodies, either alone or as immunoconjugates attached to anti-viral agents, as well as in combination with other anti-viral agents. The breadth of the claims in the new patent is noteworthy since it includes methods for treating all viruses in humans and in animals.

According to the company, targeting PS provides a broad platform for treating viral infections. Because the PS target is host-derived rather than pathogen-derived, PS-targeting antibodies are also expected to be much less susceptible to the viral genomic mutations that lead to anti-viral drug resistance.

Steven King, president and CEO of Peregrine, said: "This broad anti-viral patent further expands our intellectual property leadership in the field of PS-targeting antibodies at a time when our anti-viral program is experiencing a rising tide of interest and activity. We are especially pleased at the scope of the issued claims in this new patent, which covers the use of bavituximab and similar antibodies in the treatment of any and all virus infections.

“Antibodies falling under the scope of this new patent have already demonstrated promising anti-viral activity in clinical trials in patients with hepatitis C virus (HCV) infection and are the focus of our ongoing research funded by a Transformational Medical Technologies Initiative contract to study the potential of these agents as broad spectrum viral hemorrhagic fever therapeutics."

http://www.pharmaceutical-business-review.com/news/peregrine…

[funworker1]

bis zum früjahr stehen wir auf jeden fall bei 10$.
an dieser aussage lasse ich mich messen und gebe einen kasten bier aus, wenn es nicht so kommt.

es sollten bis dahin die ergebnisse der 3x phase2 vorliegen, eventuell partnerschaft cotara, wachsende umsätz avid, eventuell phase3 cotara, vielleicht auch schon phase3 ankündigung bavituximab, allgemeine kooperation......

sollte doch was gehen

prost
funworker

[funworker1]

wir können uns ja dann irgendwo in der mitte von deutschland treffen und den kasten plattmachen. sollte es doch so kommen, können wir das ja auch machen und einfach feiern. aber die abschlussfeier findet erst nach der übernahme statt. 2kkk

[funworker1]

institutional interest von 3,90% auf 4,25% gestiegen

[funworker1]

habt ihr euch mal den wochenchart von 2006 - heute angeschaut und die hochs vom 05.6.2006 und 29.05.2007 verbunden. wir haben in den letzten tagen fast genau auf dem abwährtstrend aufgesetzt und sind abgeprallt. ich denk zwar, daß bei pphm die charttechnik nicht so wichtig ist. aber interessant ist es dennoch.

[funworker1]

vielleicht sehen wir in den nächsten wochen nochmal 2.50 -2.80.
in meinen rosaroten augen sollte das zum nachkaufen genutzt werden.
selbst wenn der kurs nicht unglaublich steigt und pphm verkauft wird, dann aber nicht für diesen lächerlichen preis. somit ist man mit diesen käufen auf jeden fall auf der sicheren seite. klar ist nur der TOT sicher: es kann noch immer ein totalverlust werden. aber die wahrscheinlichkeit ist nahe bei null.

[funworker1]

sehr schön, sind schon unter 3 $, legt ein limit zwischen 2,50 - 2,80 und freut ich im frühling......

[funworker1]

............

[funworker1]

Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
- Successfully Completed Enrollment in Two Phase II Cancer Studies and Reported Positive Interim Clinical Data from its Cotara and Bavituximab Clinical Programs -
- Positioned Bavituximab for Definitive NSCLC Phase II Trials in Early 2010 Following Recent Successful Meeting with the FDA -
- Higher Total Revenue Led to Reduced Net Loss Compared to Prior Year and Helped Improve the Company's Cash Position -

TUSTIN, Calif., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparable prior year quarter. This increase in total revenue was primarily derived from increases in contract manufacturing services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

Avid generated manufacturing revenue of $5,308,000 for the second quarter of FY 2010, compared to $983,000 for the comparable prior year quarter, an increase of 440%. The increase in Avid revenue reflects increased manufacturing services provided to third-party customers during the quarter. Peregrine also generated revenue from services provided under its contract with the U.S. Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI) to evaluate bavituximab as a potential broad-spectrum treatment for viral hemorrhagic fever infections. Government contract revenue was $1,510,000 for the second quarter of FY 2010, compared to $958,000 for the prior year quarter, an increase of 58%.

Total costs and expenses in the second quarter of FY 2010 increased $2,942,000 to $9,433,000, compared to $6,491,000 in the second quarter of FY 2009, an increase of 45%. The current quarter increase in total costs and expenses was primarily due to an increase in the costs of contract manufacturing during the quarter of $2,877,000, related to higher reported contract manufacturing revenue. Research and development (R&D) expenses slightly decreased by $169,000 (4%) to $4,132,000 in the second quarter of FY 2010, from $4,301,000 in the prior year quarter, primarily reflecting the reduced resource needs of Peregrine's current clinical programs as they complete patient dosing and advance into the patient follow-up and analysis phase. Selling, general, and administrative (SG&A) expenses increased in the second quarter of FY 2010 to $1,761,000, compared to $1,527,000 in the second quarter of FY 2009, an increase of 15%, primarily reflecting the company's recent investments in acquiring additional expertise to support its contract manufacturing business.

Peregrine's consolidated net loss decreased 38% to $2,787,000 or $0.06 per basic and diluted share in the second quarter of FY 2010, compared to the consolidated net loss of $4,497,000, or $0.10 per basic and diluted share for the same prior year period. At October 31, 2009, the company had $13.6 million in cash and cash equivalents.

"Peregrine continued to achieve important gains in every area of its operations since the start of the second quarter," said Steven W. King, president and CEO of Peregrine. "Since the last earnings call, we completed patient enrollment in our Cotara dosimetry brain cancer trial and in two bavituximab Phase II trials in breast cancer and non-small cell lung cancer (NSCLC). We also reported positive initial data from the bavituximab NSCLC trial and from an ongoing Cotara Phase II study, with both showing promising progression-free-survival data. We recruited two world-class cancer drug development experts -- adding Dr. Bruce Chabner of Harvard Medical School and Massachusetts General Hospital as a clinical advisor and former Genentech regulatory chief Dr. Robert Garnick to our management team as head of regulatory -- and we made organizational enhancements at Avid Bioservices as we prepare for continued growth of its business. We accomplished all of this while continuing to report increased revenue from our Avid contract manufacturing business and from our government contract, resulting in a decreased net loss. These positive developments have helped position us to initiate the next round of clinical trials that we are planning to start in the early part of next year, as clinical resources are being freed up as our current Phase II trials near completion. These advances are setting the stage for what we expect to be a very positive 2010 for the company."

Dr. Robert Garnick, Peregrine's head of regulatory, commented, "I am delighted that we have already been able to make significant progress in advancing bavituximab in just the few months that I have been working with the company. By working with our clinical advisors and the FDA, we have been able to position ourselves to initiate definitive bavituximab NSCLC Phase II "proof-of-concept" clinical studies in early 2010 as part of our plans to advance the program. Based on the results seen to date, we believe bavituximab has considerable potential in multiple solid tumor indications and we look forward to exploring a number of these in additional upcoming trials. Our goal is to seek clinical and regulatory pathways that will expedite our progress towards possible commercialization while also ensuring a strong positioning for this novel product. We also look forward to developing a similar strategy for the Cotara brain cancer program as we obtain additional data from the recently completed dosimetry trial and from our ongoing Phase II study in patients with glioblastoma, a condition for which safe and effective new therapies are urgently needed.

Mr. King added, "We are also very pleased at the good progress we are making in our anti-viral efforts. Our federally-funded biodefense initiative to develop our PS-targeting antibodies for the prevention and treatment of viral hemorrhagic fever infections (VHF) is proceeding well as evidenced by the promising data from the program recently presented at an important biodefense conference. This quarter, our scientific collaborators secured a substantial grant to expand the study of our PS-targeting antibodies in VHF. In addition, we reorganized our infectious diseases program infrastructure to ensure that the many opportunities potentially available to Peregrine and our collaborators for commercially-relevant applications of our technology to treat infectious diseases are fully exploited."

Mr. King continued, "Our Avid contract manufacturing subsidiary continued to report positive revenue growth this quarter while establishing an impressive global alliance partnership. We added additional talent to the strong team already on board at Avid with the hiring of a senior global operations and productivity executive and an experienced vice president of business operations. This team is focusing both on continuing to grow Avid's contract manufacturing business and on building a new business in the emerging field of biosimilars, an area in which we believe we are very well-equipped to compete and where we also see nearer-term commercialization opportunities."

"This has been an eventful quarter for Peregrine, as we continued the advancement of our key clinical programs while significantly reducing our net loss and increasing our cash position quarter-over-quarter," said Paul Lytle, chief financial officer of Peregrine. "We look forward to sharing our enthusiasm for Peregrine's future prospects with the investment community through an active investor outreach program planned throughout the upcoming year."

Mr. King concluded, "Looking to the future, we are turning our attention to the goal of advancing at least one and possibly multiple products to the market within the next 2.5 to 5 years. The promising data we have seen to date from all of our ongoing trials, the addition of world class clinical and regulatory expertise to our team and the strategic asset we have in Avid Bioservices are helping to fuel this drive. We have already begun working on a number of fronts to strengthen our ability to achieve this goal and we look forward to sharing those plans as we transition into the new year."

FY 2010 Recent Highlights

Bavituximab Anti-Cancer Program

Peregrine reported progress in all three ongoing Phase II trials in its bavituximab cancer program:

-- Reported 61% objective response rate in 46-patient Phase II trial
evaluating bavituximab in combination with docetaxel in advanced breast
cancer patients, exceeding the 41% tumor response data for docetaxel as
monotherapy that was used as the benchmark for the design of this study.
With these positive initial data in hand, Peregrine reported that it is
assessing possible trial designs for future studies.
-- Reported that enrollment was completed in a 49-patient Phase II trial
evaluating bavituximab in combination with carboplatin and paclitaxel in
non-small cell lung cancer (NSCLC) patients with locally advanced or
metastatic disease. Analysis from the initial 21-patient cohort in this
trial showed that the median progression-free-survival (PFS) was 6.5
months, which is superior to the PFS range of 4.2 to 4.5 months reported
in a similar patient population receiving carboplatin and paclitaxel as
a single agent in the NSCLC trials that were the basis for the design of
this trial.
-- Completed enrollment of the planned 46 patients in a Phase II trial
evaluating bavituximab in combination with carboplatin and paclitaxel in
advanced breast cancer patients. Peregrine previously reported that
nine of 14, or 64% of evaluable patients in the initial cohort of this
trial achieved an objective tumor response according to RECIST criteria.
These data exceeded the pre-specified endpoint needed to expand the
trial and compare favorably with historical results with chemotherapy
alone. Patient dosing and follow-up in this trial are continuing.
-- Announced issuance of a new U.S. patent with claims covering the use of
bavituximab in combination with a broad range of cancer therapeutic
agents. The combinations of bavituximab with docetaxel or carboplatin
and paclitaxel, which have shown promising initial results in
Peregrine's Phase II trials, are all covered under the claims of this
patent. The additional protection it provides further strengthens
Peregrine's intellectual property leadership in the field of
phosphatidylserine (PS)-targeting therapeutics
-- Published a new study in Clinical Cancer Research showing the
therapeutic promise of bavituximab with radiation in a lethal brain
cancer model. A PS-targeting antibody similar to bavituximab
demonstrated potent anti-tumor activity when combined with radiation in
a model of aggressive brain cancer, doubling the survival time of test
animals and producing long-term cures. The study also provided
additional evidence that PS-targeting antibodies employ multiple novel
mechanisms to mobilize the immune system to combat cancer and that these
mechanisms are enhanced by concurrent radiation therapy.
-- Announced that noted cancer researcher Bruce Chabner, M.D., will serve
as a clinical advisor on the design of clinical trials for the
bavituximab and Cotara cancer programs. Dr. Chabner is currently the
clinical director of Massachusetts General Hospital (MGH) Cancer Center,
chief of hematology and oncology at MGH and a professor of medicine at
Harvard Medical School. Previously, Dr. Chabner had a distinguished
25-year career at the National Cancer Institute.


Bavituximab Anti-Viral Program

The company advanced its PS-targeting anti-viral program on a number of fronts:

-- Presented promising interim data at the 2009 Chemical and Biological
Defense Science and Technology Conference from Peregrine's program to
assess the company's PS-targeting antibodies as broad-spectrum agents
for the treatment of viral hemorrhagic fevers (VHF), a potential
biodefense threat. Researchers confirmed broad spectrum PS-targeting
antibody binding to VHF viral particles and also to mammalian cells
infected with hemorrhagic fever viruses. Initial anti-viral efficacy
studies were encouraging, showing that a single dose of a PS-targeting
antibody increased the survival of hamsters infected with lethal doses
of viruses from two different VHF families. Based on these findings,
additional efficacy studies are now underway.
-- Formed anti-viral research group to oversee the company's anti-PS
infectious disease collaborations. The new group has responsibility for
coordinating, expanding and leveraging the company's multiple external
collaborations to assess the potential utility of Peregrine's
PS-targeting antibody platform for the prevention and treatment of
serious infectious diseases, including viral hemorrhagic fevers and
other biodefense threats, HIV, influenza, cytomegalovirus, leishmaniasis
and malaria. Peregrine's broad-spectrum PS-targeting antibodies are
being assessed in anti-infective applications by more than a dozen
leading research institutions.
-- Was awarded a second broad U.S. patent for anti-viral applications of
Peregrine's phospholipid-targeting antibodies that includes broad claims
covering anti-viral uses of PS-targeting antibodies including
bavituximab. The new patent covers compositions and methods of treating
virus infections using bavituximab and similar antibodies, either alone
or as immunoconjugates attached to anti-viral agents, as well as in
combination with other anti-viral agents. The broad claims include
methods for treating all viruses in humans and animals.
-- Announced that research colleagues at the University of Texas
Southwestern Medical Center received a two-year $763,000 grant from the
U.S. National Institute of Allergy and Infectious Diseases (NIAID) for
research expanding studies of anti-PS antibodies as potential treatments
for viral hemorrhagic fever infections.


Cotara(R) Brain Cancer Program

Peregrine reported significant progress in the Cotara brain cancer program:

-- Completed patient enrollment in the Cotara dose confirmation and
dosimetry trial at U.S. brain cancer centers, meeting all of the
dosimetry data-gathering objectives of the study. Patients in the
initial two cohorts of this study have all either met or exceeded the
expected median survival time of six months for recurrent glioblastoma
multiforme (GBM) patients. Peregrine also reported that the ongoing
Phase II Cotara brain cancer trial would be expanded to clinical sites
that had participated in the dosimetry trial.
-- Presented interim Phase II data at the XIV World Congress of
Neurological Surgery Annual Meeting showing that Cotara appeared well
tolerated and demonstrated encouraging signs of efficacy in patients
with GBM. Researchers presented interim data on 10 recurrent GBM
patients at first relapse. Using the clinical site's institutional
definitions, the interim median recurrence-free survival of these
patients was 33 weeks and the interim median overall survival was 40.6
weeks. This compares favorably with historical data on expected
survival for patients with GBM, which is approximately 24 weeks from
time of disease recurrence. Based on this data, the study authors
conclude that Cotara appears to be feasible, tolerable and has
encouraging signs of efficacy in recurrent GBM patients.




Copyright (C) 2009 PR Newswire. All rights reserved

[funworker1]

so, das ist jetzt mein letzter kommentar bis ! .......
1 PPHM ist pleite
2 Übernahme
3 Kurs erreicht ca. 9$

viel spaß